

FILE 'REGISTRY' ENTERED AT 16:08:48 ON 17 DEC 2008

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 2658 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 35 S L4
L6 733 S L4 SSS FULL
L7 1925 S L3 NOT L6

FILE 'HCAPLUS' ENTERED AT 16:10:34 ON 17 DEC 2008

L8 302 S L7/THU
L9 22211 S FLUOROURACIL
L10 85 S L8 AND L9
L11 4 S L10 AND (PY<1990 OR AY<1990 OR PRY<1990)

FILE 'STNGUIDE' ENTERED AT 16:11:30 ON 17 DEC 2008

FILE 'HCAPLUS' ENTERED AT 16:23:39 ON 17 DEC 2008

L12 1263057 S TOXICITY OR CHEMOTHERAP? OR (SIDE EFFECT) OR CANCER OR TUMOR
L13 214 S L8 AND L12
L14 658 S URIDINE PHOSPHORYLASE
L15 7 S L13 AND L14
L16 43 S L13 AND (PY<1994 OR AY<1994 OR PRY<1994)
L17 38269 S FLUOROURACIL OR FLUOROURIDINE OR FLUOROCYTOSINE OR DEOXYURIDI
L18 115 S L13 AND L17
L19 10 S L18 AND (PY<1994 OR AY<1994 OR PRY<1994)

FILE 'REGISTRY' ENTERED AT 16:53:21 ON 17 DEC 2008

L20 STRUCTURE UPLOADED
L21 50 S L20
L22 1084 S L20 SUB=L7 FULL

FILE 'HCAPLUS' ENTERED AT 16:54:43 ON 17 DEC 2008

L23 80 S L22/THU
L24 12 S L23 AND (PY<1995 OR AY<1995 OR PRY<1995)
L25 39 S TRIACETYLRIDINE
L26 25 S L25 AND (PY<1995 OR AY<1995 OR PRY<1995)
L27 3 S ETHOXYCARBONYLRIDINE
L28 0 S TRIACRTYLCYTIDINE
L29 13 S TRIACETYLCYTIDINE
L30 10 S L29 AND (PY<1995 OR AY<1995 OR PRY<1995)

FILE 'REGISTRY' ENTERED AT 14:23:04 ON 19 DEC 2008
 EXP 5-FLUOROOROTATE/CN
 L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 14:23:40 ON 19 DEC 2008
 L2 281 S L1
 L3 38059 S URIDINE OR CYTIDINE
 L4 44 S L2 AND L3
 L5 36 S L4 AND (PY<1993 OR AY<1993 OR PRY<1993)

FILE 'HCAPLUS' ENTERED AT 14:24:42 ON 19 DEC 2008
 L6 STRUCTURE UPLOADED
 S L6

FILE 'REGISTRY' ENTERED AT 14:25:28 ON 19 DEC 2008
 L7 1387 S L6 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:25:29 ON 19 DEC 2008
 L8 10564 S L7 SSS FULL

FILE 'REGISTRY' ENTERED AT 14:25:40 ON 19 DEC 2008
 L9 STRUCTURE UPLOADED
 L10 303 S L9 SUB=L7 FULL
 L11 1084 S L7 NOT L10

FILE 'HCAPLUS' ENTERED AT 14:26:28 ON 19 DEC 2008
 L12 1462 S L11
 L13 6 S L2 AND L12
 L14 27122 S MALARIA OR ANTIMALARIAL
 L15 3 S L12 AND L14

FILE 'HCAPLUS' ENTERED AT 15:41:15 ON 19 DEC 2008
 S URIDINE/CN

FILE 'REGISTRY' ENTERED AT 15:41:22 ON 19 DEC 2008
 L16 1 S URIDINE/CN

FILE 'HCAPLUS' ENTERED AT 15:41:22 ON 19 DEC 2008
 L17 7325 S L16

FILE 'REGISTRY' ENTERED AT 15:41:31 ON 19 DEC 2008
 L18 1 S URIDINE/CN
 L19 1 S CYTIDINE/CN

FILE 'HCAPLUS' ENTERED AT 15:41:48 ON 19 DEC 2008
 L20 390 S L18/THU OR L19/THU
 L21 536186 S CANCER OR ANTITUMOR
 L22 143 S L20 AND L21
 L23 15 S L22 AND (PY<1993 OR AY<1993 OR PRY<1993)
 L24 145941 S ANTIVIRAL OR HIV OR (HUMAN IMMUNODEFICIENCY) OR AZT
 L25 58 S L20 AND L24
 L26 5 S L25 AND (PY<1993 OR AY<1993 OR PRY<1993)
 L27 27200 S MALARIA OR ANTIMALARIAL OR FLUOROOROTATE
 L28 3 S L20 AND L27

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:08:48 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2008 HIGHEST RN 1085590-90-4
DICTIONARY FILE UPDATES: 16 DEC 2008 HIGHEST RN 1085590-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\08460186acylated.str



```

chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 30 31 32 33 34 35 38 39 41
42 43 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 24 25 26 27 28 29
chain bonds :
1-15 1-21 2-14 2-22 3-16 3-23 5-20 5-47 7-12 8-42 9-13 10-18 11-19
14-39
15-41 16-17 17-38 25-30 27-31 28-32 29-33 31-43 34-35
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11 24-29 24-25 25-26
26-27
27-28 28-29
exact/norm bonds :
1-2 1-5 1-15 2-3 2-14 3-4 4-5 5-47 6-11 6-7 7-8 7-12 8-9 8-42 9-10
9-13 10-11 14-39 15-41 17-38 24-29 24-25 25-26 25-30 26-27 27-28 27-31
28-29 31-43 34-35

exact bonds :
1-21 2-22 3-16 3-23 5-20 10-18 11-19 16-17 28-32 29-33

```

G1:H, [*1]

G2:[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 38:CLASS 39:CLASS 41:CLASS 42:CLASS
43:CLASS 47:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 16:09:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2177 TO ITERATE

91.9% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 40742 TO 46338


PROJECTED ANSWERS: 1983 TO 3371

L2 50 SEA SSS SAM L1

=> d l2 scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,4(1H,3H)-Pyrimidinedione, 1-(β -D-arabinofuranosyl-5-C-t)- (9CI)
MF C9 H11 N2 O6 T


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cytidine, N-(1H-benzotriazol-1-ylmethyl)- (9CI)
MF C16 H18 N6 O5


Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α -[16-[(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[3-[[2-[2-[2-[(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-thioxoethoxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7-dioxo-16-thioxo-11,14-dioxo-3,8-diazahexadec-1-yl]- ω -methoxy- (9CI)
 MF (C2 H4 O)_n C58 H87 N13 O26 S3
 CI PMS


PAGE 1-A




PAGE 1-B




PAGE 1-C





L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Carbamic acid, [2-[(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C18 H28 N4 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full

FULL SEARCH INITIATED 16:09:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 43389 TO ITERATE

100.0% PROCESSED 43389 ITERATIONS
 SEARCH TIME: 00.00.01


2658 ANSWERS

L3

2658 SEA SSS FUL L1

=>

Uploading C:\Program Files\STNEXP\Queries\08460186not.str



```
chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 30 31 32 33 34 35 37 38 39
43
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 24 25 26 27 28 29
chain bonds :
1-15 1-21 2-14 2-22 3-16 3-23 5-20 5-43 7-12 8-38 9-13 10-18 11-19
14-35
15-37 16-17 17-34 25-30 27-31 28-32 29-33 31-39
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11 24-29 24-25 25-26
26-27
27-28 28-29
exact/norm bonds :
1-2 1-5 1-15 2-3 2-14 3-4 4-5 5-43 6-11 6-7 7-8 7-12 8-9 9-10 9-13
10-11 24-29 24-25 25-26 25-30 26-27 27-28 27-31 28-29
```

exact bonds :
1-21 2-22 3-16 3-23 5-20 8-38 10-18 11-19 14-35 15-37 16-17 17-34 28-32
29-33 31-39

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS 39:CLASS 43:CLASS

L4 STRUCTURE UPLOADED

=> s 14

SAMPLE SEARCH INITIATED 16:10:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2177 TO ITERATE

91.9% PROCESSED 2000 ITERATIONS 35 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 40742 TO 46338
PROJECTED ANSWERS: 391 TO 1131

L5 35 SEA SSS SAM L4

=> s 14 sss full

FULL SEARCH INITIATED 16:10:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 43389 TO ITERATE

100.0% PROCESSED 43389 ITERATIONS 733 ANSWERS
SEARCH TIME: 00.00.01

L6 733 SEA SSS FUL L4

=> s 13 not 16

L7 1925 L3 NOT L6

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	357.18	357.39

FILE 'HCAPLUS' ENTERED AT 16:10:34 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 16 Dec 2008 (20081216/ED)

HCAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s 17/thu
      2045 L7
      1078334 THU/RL
L8      302 L7/THU
      (L7 (L) THU/RL)
```

```
=> s fluorouracil
L9      22211 FLUOROURACIL
```

```
=> s 18 and 19
L10      85 L8 AND L9
```

```
=> s 110 and (PY<1990 or AY<1990 or PRY<1990)
      13219824 PY<1990
      2279642 AY<1990
      1715876 PRY<1990
L11      4 L10 AND (PY<1990 OR AY<1990 OR PRY<1990)
```

```
=> d 111 1-4 ti abs bib
```

```
L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Treatment of chemotherapeutic agent and antiviral agent toxicity with
acylated pyrimidine nucleosides
AB Compsds., compns., and methods are disclosed for treatment and prevention
of toxicity due to chemotherapeutic agents and antiviral agents.
Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides.
These compds. are capable of attenuating damage to the hematopoietic
system in animals receiving antiviral or antineoplastic chemotherapy.
AN 1999:670113 HCAPLUS <<LOGINID::20081217>>
DN 131:281604
TI Treatment of chemotherapeutic agent and antiviral agent toxicity with
acylated pyrimidine nucleosides
IN Von Borstel, Reid; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 13
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5968914	A	19991019	US 1995-472210	19950607 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--

EP 712629	B1	20030618		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 10001436	A	19980106	JP 1997-36734	19881027 <--
JP 3474073	B2	20031208		
JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
CA 2111571	A1	19930121	CA 1992-2111571	19920625
CA 2111571	C	20050823		
CA 2504078	A1	19930121	CA 1992-2504078	19920625
CA 2504078	C	20070828		
ES 2160579	T3	20011116	ES 1992-914215	19920625
ZA 9204975	A	19930428	ZA 1992-4975	19920703
IN 175688	A1	19950812	IN 1992-CA473	19920706
US 5246708	A	19930921	US 1992-911379	19920713 <--
US 5470838	A	19951128	US 1992-997657	19921230 <--
US 5583117	A	19961210	US 1993-140475	19931025 <--
US 6020320	A	20000201	US 1993-153163	19931117 <--
US 5736531	A	19980407	US 1993-176485	19931230 <--
IN 177670	A1	19970215	IN 1994-CA701	19940902
US 5770582	A	19980623	US 1995-419767	19950410 <--
US 5691320	A	19971125	US 1995-465454	19950605 <--
US 6054441	A	20000425	US 1995-463790	19950605 <--
US 6060459	A	20000509	US 1995-465016	19950605 <--
US 7307166	B1	20071211	US 1995-463771	19950605 <--
US 6258795	B1	20010710	US 1995-466145	19950606 <--
US 6316426	B1	20011113	US 1995-466144	19950606 <--
US 6232298	B1	20010515	US 1995-479519	19950607 <--
US 6274563	B1	20010814	US 1995-479349	19950607 <--
US 6348451	B1	20020219	US 1995-478736	19950607 <--
US 6919320	B1	20050719	US 1995-473331	19950607 <--
CA 2223640	A1	19961219	CA 1996-2223640	19960606
WO 9640165	A1	19961219	WO 1996-US10067	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9661114	A	19961230	AU 1996-61114	19960606
AU 724805	B2	20000928		
EP 831849	A1	19980401	EP 1996-918461	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1192149	A	19980902	CN 1996-195929	19960606
JP 10511689	T	19981110	JP 1997-502184	19960606
JP 2003201240	A	20030718	JP 2003-721	19960606
EP 1491201	A1	20041229	EP 2004-23557	19960606
EP 1491201	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL				
AT 320813	T	20060415	AT 2004-23557	19960606
ES 2257721	T3	20060801	ES 2004-23557	19960606
PT 1491201	T	20060831	PT 2004-23557	19960606
HK 1072897	A1	20060512	HK 2005-105421	19981003
US 20010025032	A1	20010927	US 1999-249790	19990216 <--
US 6344447	B2	20020205		
AU 9952624	A	19991202	AU 1999-52624	19991001
US 6743782	B1	20040601	US 2000-494242	20000131 <--
AU 2002320811	A1	20030403	AU 2002-320811	20021223
US 20040033981	A1	20040219	US 2003-601863	20030624 <--
US 20040192635	A1	20040930	US 2004-824501	20040415 <--
US 20040220134	A1	20041104	US 2004-855835	20040528 <--

	AU 2005232288	A1	20051201	AU 2005-232288	20051110
	JP 2006137772	A	20060601	JP 2005-380457	20051228 <--
	JP 2008019268	A	20080131	JP 2007-233452	20070907 <--
PRAI	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205		
	US 1991-724340	B2	19910705		
	US 1992-903107	B2	19920625		
	US 1993-61381	B2	19930514		
	US 1993-176485	A2	19931230		
	US 1988-186031	B2	19880425	<--	
	EP 1988-910239	A3	19881027	<--	
	JP 1988-509176	A3	19881027	<--	
	JP 1994-303877	A3	19881027	<--	
	JP 2000-379524	A3	19881027	<--	
	US 1989-341925	B1	19890421	<--	
	US 1990-533933	B1	19900605		
	US 1990-438493	B2	19900626		
	US 1991-653882	B2	19910208		
	US 1991-737913	B3	19910729		
	CA 1992-2111571	A3	19920625		
	IN 1992-CA473	A1	19920706		
	US 1992-911379	A3	19920713		
	US 1992-925931	B2	19920807		
	US 1992-958598	B3	19921007		
	US 1992-987730	B2	19921208		
	US 1992-997657	A3	19921230		
	US 1993-96407	B1	19930726		
	US 1993-98884	B1	19930729		
	US 1993-153163	A1	19931117		
	US 1993-158799	B2	19931201		
	US 1994-266897	B3	19940701		
	US 1994-289214	A3	19940812		
	US 1995-419767	A3	19950410		
	US 1995-463740	A1	19950605		
	US 1995-472210	A	19950607		
	AU 1995-29150	A3	19950630		
	EP 1996-918461	A3	19960606		
	JP 1997-502184	A3	19960606		
	WO 1996-US10067	W	19960606		
	HK 1998-111095	A3	19981003		
	AU 1999-52624	A3	19991001		
	US 2000-494242	A3	20000131		
	AU 2002-320811	A3	20021223		
	JP 2005-380457	A3	20051228		

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
 AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Thus, biol activity of 5-fluorouracil is reported.
 AN 1998:236253 HCAPLUS <<LOGINID::20081217>>
 DN 128:266247

OREF 128:52559a,52562a

TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides

IN Von Borstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5736531	A	19980407	US 1993-176485	19931230 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625
	ZA 9204975	A	19930428	ZA 1992-4975	19920703
	IN 175688	A1	19950812	IN 1992-CA473	19920706
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	US 5770582	A	19980623	US 1995-419767	19950410 <--
	US 5691320	A	19971125	US 1995-465454	19950605 <--
	US 6054441	A	20000425	US 1995-463790	19950605 <--
	US 6060459	A	20000509	US 1995-465016	19950605 <--
	US 7307166	B1	20071211	US 1995-463771	19950605 <--
	US 6258795	B1	20010710	US 1995-466145	19950606 <--
	US 6316426	B1	20011113	US 1995-466144	19950606 <--
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	US 6232298	B1	20010515	US 1995-479519	19950607 <--
	US 6274563	B1	20010814	US 1995-479349	19950607 <--
	US 6348451	B1	20020219	US 1995-478736	19950607 <--
	US 6919320	B1	20050719	US 1995-473331	19950607 <--
	US 7166581	B1	20070123	US 1995-473330	19950607 <--
	US 20010025032	A1	20010927	US 1999-249790	19990216 <--
	US 6344447	B2	20020205		
	AU 9952624	A	19991202	AU 1999-52624	19991001
	US 6743782	B1	20040601	US 2000-494242	20000131 <--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	US 20040033981	A1	20040219	US 2003-601863	20030624 <--
	US 20040192635	A1	20040930	US 2004-824501	20040415 <--
	US 20040220134	A1	20041104	US 2004-855835	20040528 <--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
	JP 2006137772	A	20060601	JP 2005-380457	20051228 <--
	JP 2008019268	A	20080131	JP 2007-233452	20070907 <--
PRAI	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205		
	US 1991-724340	B2	19910705		
	US 1992-903107	B2	19920625		

US 1993-61381	B2	19930514	
US 1988-186031	B2	19880425	<--
EP 1988-910239	A3	19881027	<--
JP 1988-509176	A3	19881027	<--
JP 1994-303877	A3	19881027	<--
JP 2000-379524	A3	19881027	<--
US 1989-341925	B1	19890421	<--
US 1990-533933	B1	19900605	
US 1990-438493	B2	19900626	
US 1991-653882	B2	19910208	
US 1991-737913	B3	19910729	
CA 1992-2111571	A3	19920625	
IN 1992-CA473	A1	19920706	
US 1992-911379	A3	19920713	
US 1992-925931	B2	19920807	
US 1992-958598	B3	19921007	
US 1992-987730	B2	19921208	
US 1992-997657	A3	19921230	
US 1993-96407	B1	19930726	
US 1993-98884	B1	19930729	
US 1993-153163	A1	19931117	
US 1993-158799	B2	19931201	
US 1993-176485	A2	19931230	
US 1994-266897	B3	19940701	
US 1994-289214	A3	19940812	
US 1995-419767	A3	19950410	
US 1995-463740	A1	19950605	
US 1995-472210	A1	19950607	
AU 1995-29150	A3	19950630	
AU 1999-52624	A3	19991001	
US 2000-494242	A3	20000131	
AU 2002-320811	A3	20021223	
JP 2005-380457	A3	20051228	

OS MARPAT 128:266247

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.

AN 1997:141015 HCAPLUS <<LOGINID::20081217>>

DN 126:139905

OREF 126:26891a

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

IN Vonborstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 10511689	T	19981110	JP 1997-502184	19960606
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1995-472210	A	19950607		
	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205		
	US 1991-724340	B2	19910705		
	US 1992-903107	B2	19920625		
	IN 1992-CA473	A1	19920706		
	US 1993-61381	B2	19930514		
	US 1993-176485	A2	19931230		
	AU 1995-29150	A3	19950630		
	WO 1996-US10067	W	19960606		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Comparative chemotherapy of AKR lymphoma and human hematological neoplasia
 AB Melphalan (I) [148-82-3] (7.7 mg/kg 4 times daily for 12 days) caused a 118% increase in life span of AKR mice with spontaneous lymphoma, as compared to a 75% life span increase when early L1210 leukemia was used for the assay. Several other antitumor drugs, including 5-fluorouracil (II) [51-21-8], vinblastine [865-21-4], daunorubicin [20830-81-3], 6-mercaptopurine [50-44-2], and procarbazine [671-16-9] were in reasonably good agreement in both systems, when they were compared at their optimal dosages for each system. The effectiveness of 27 chemotherapeutic drugs was tested in AKR mice with spontaneous lymphoma and the results were compared with those in L1210 transplanted tumors and with clin. information. The data indicated there is possibly a better correspondence of spontaneous AKR with non-Hodgkin's lymphoma and myeloma than for other hematol. cancers. There was no advantage in using the spontaneous AKR system for primary screening as compared to the early leukemia L1210 system. The AKR system might be useful for studying remission induction and maintenance, and for evaluation of prophylactic treatment as well as reinduction.

AN 1974:103722 HCAPLUS <<LOGINID::20081217>>

DN 80:103722

OREF 80:16627a,16630a

TI Comparative chemotherapy of AKR lymphoma and human hematological neoplasia
 AU Frei, Emil III; Schabel, Frank M., Jr.; Goldin, Abraham
 CS Child. Cancer Res. Found., Boston, MA, USA

SO Cancer Research (1974), 34(1), 184-93
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.02	374.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'STNGUIDE' ENTERED AT 16:11:30 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 12, 2008 (20081212/UP).

=> d his

(FILE 'HOME' ENTERED AT 16:08:41 ON 17 DEC 2008)

FILE 'REGISTRY' ENTERED AT 16:08:48 ON 17 DEC 2008

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 2658 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 35 S L4
L6 733 S L4 SSS FULL
L7 1925 S L3 NOT L6

FILE 'HCAPLUS' ENTERED AT 16:10:34 ON 17 DEC 2008

L8 302 S L7/THU
L9 22211 S FLUOROURACIL
L10 85 S L8 AND L9
L11 4 S L10 AND (PY<1990 OR AY<1990 OR PRY<1990)

FILE 'STNGUIDE' ENTERED AT 16:11:30 ON 17 DEC 2008

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.20	375.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'HCAPLUS' ENTERED AT 16:23:39 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 16 Dec 2008 (20081216/ED)

HCAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s toxicity or chemotherap? or (side effect) or cancer or tumor or neopla?
      374601 TOXICITY
      115832 CHEMOTHERAP?
      693402 SIDE
      5041750 EFFECT
      15270 SIDE EFFECT
          (SIDE(W)EFFECT)
      385692 CANCER
      477621 TUMOR
      571919 NEOPLA?
L12   1263057 TOXICITY OR CHEMOTHERAP? OR (SIDE EFFECT) OR CANCER OR TUMOR OR
      NEOPLA?
```

```
=> s 18 and 112
L13   214 L8 AND L12
```

```
=> s uridine phosphorylase
      29222 URIDINE
      19577 PHOSPHORYLASE
L14   658 URIDINE PHOSPHORYLASE
      (URIDINE(W)PHOSPHORYLASE)
```

```
=> s 113 and 114
L15   7 L13 AND L14
```

```
=> d 115 1-7 ti abs bib hitstr
```


```
L15   ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI    Pyrimidine nucleotide precursors for treatment of systemic inflammation
      and inflammatory hepatitis
AB    The invention discloses pyrimidine nucleotide precursors, including acyl
      derivs. of cytidine, uridine, and orotic acid, and uridine
      phosphorylase inhibitors, for use in enhancing resistance to
      sepsis or systemic inflammation.
AN    2006:449364 HCAPLUS <<LOGINID::20081217>>
DN    144:445360
TI    Pyrimidine nucleotide precursors for treatment of systemic inflammation
      and inflammatory hepatitis
IN    Bamat, Michael Kevin; Hilt-Brand, Bradley M.; Borstel, Reid Warren Von
PA    Pro-Neuron, Inc., Australia
SO    Aust. Pat. Appl., 81 pp.
      CODEN: AUXXCM
DT    Patent
```

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	AU 2004201154	A1	20040422	AU 2004-201154	20040318
	AU 2006236108	A1	20061207	AU 2006-236108	20061121
PRAI	AU 2001-24913	A3	20010307		
	AU 2004-201154	A3	20040318		
IT	4105-38-8				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis)				
RN	4105-38-8 HCAPLUS				
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.



L15 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy

AB Purpose: The purpose of this investigation was to study the effects of combining oral 5-(phenylselenenyl)acyclouridine (PSAU) with 2',3',5'-tri-O-acetyluridine (TAU) on the levels of plasma uridine in mice. PSAU is a new lipophilic and potent inhibitor of uridine phosphorylase (UrdPase, EC 2.4.2.3), the enzyme responsible for uridine catabolism. PSAU has 100% oral bioavailability and is a powerful enhancer of the bioavailability of oral uridine. TAU is a prodrug of uridine and a far superior source of uridine than uridine itself. Methods: Oral TAU was administered to mice alone or with PSAU. The plasma levels of uridine and its catabolites as well as PSAU were measured using HPLC and pharmacokinetic anal. was performed. Results: Oral administration of 2000 mg/kg TAU increased plasma uridine by over 250-fold with an area under the curve (AUC) of 754 $\mu\text{mol} \cdot \text{h/l}$. Coadministration of PSAU at 30 and 120 mg/kg with TAU further improved the bioavailability of plasma uridine resulting from the administration of TAU alone by 1.7- and 3.9-fold, resp., and reduced the C_{max} and AUC of plasma uracil. Conclusion: The exceptional effectiveness of PSAU plus TAU in elevating and sustaining a high plasma uridine concentration could be useful in the management of medical disorders that are remedied by administration of uridine, as well as the rescue or protection from host toxicities of various chemotherapeutic pyrimidine analogs.

AN 2000:597942 HCAPLUS <<LOGINID::20081217>>

DN 134:260942

TI Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine:

relevance to uridine rescue in chemotherapy

AU Ashour, Osama M.; Naguib, Fardos N. M.; Goudgaon, Naganna M.; Schinazi, Raymond F.; el Kouni, Mahmoud H.

CS Center for AIDS Research, Comprehensive Cancer Center, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA

SO Cancer Chemotherapy and Pharmacology (2000), 46(3), 235-240
CODEN: CCPHDZ; ISSN: 0344-5704

PB Springer-Verlag

DT Journal


LA English

IT 4105-38-8, 2',3',5'-Tri-O-acetyluridine
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effect of phenylselenenyl)acyclouridine on plasma concentration of uridine released from uridine prodrug triacetyluridine: relevance to uridine rescue in chemotherapy)

RN 4105-38-8 HCAPLUS

CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN


TI Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine

AB Administration of 200 mg/kg of 5-fluorouracil (FUra) to mice bearing human colon carcinoma DLD-1 xenografts resulted in 100% mortality. Oral administration of 2000 mg/kg of 2',3',5'-tri-O-acetyluridine (TAU), a prodrug of uridine, in combination with 120 mg/kg of 5-(benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA), the most potent known inhibitor of uridine phosphorylase (UrdPase, EC 2.4.2.3), 2 h after the administration of the same dose of FUra completely protected the mice (100% survival) from the toxicity of FUra. This combination also reduced tumor weight by 67% compared with 46% achieved by the maximum tolerated dose (50 mg/kg) of FUra alone. Similarly, administration of BBBA plus TAU 1 h before or 4 h after the administration of FUra reduced the tumor weight by 53 and 37%, resp. However, these schedules were less effective in protecting the host from the toxicity of FUra than when the treatment was carried out at 2 h after FUra administration. TAU alone did not protect from FUra host toxicity. The efficiency of the BBBA plus TAU combination in rescuing from FUra host toxicities is attributed to the exceptional effectiveness of this combination in raising and maintaining higher plasma uridine concns. than those achieved by TAU alone

or by equimolar doses of uridine (Ashour et al., Biochem. Pharmacol 51: 1601-1612, 1996). The present results suggest that the BBBA plus TAU combination can provide a better substitute for the massive doses of uridine required to achieve the high levels of uridine necessary to rescue or protect from FUra host toxicities without the toxic side-effects associated with such doses of uridine. The combination of TAU plus BBBA may also allow the escalation of FUra doses for better chemotherapeutic efficacy. Alternatively, the combination may be used as a rescue regimen in the occasional cases where cancer patients receive a lethal overdose of FUra.

AN 2000:400538 HCAPLUS <<LOGINID::20081217>>
 DN 133:144540
 TI Modulation of 5-fluorouracil host toxicity by
 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine
 phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a
 prodrug of uridine
 AU Ashour, O. M.; Naguib, F. N. M.; Panzica, R. P.; Al Safarjalani, O. N.; el
 Kouni, M. H.
 CS Department of Pharmacology and Toxicology, University of Alabama at
 Birmingham, Birmingham, AL, 35294, USA
 SO Biochemical Pharmacology (2000), 60(3), 427-431
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 IT 4105-38-8, 2',3',5'-Tri-O-acetyluridine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (modulation of fluorouracil host toxicity by
 (benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine
 phosphorylase inhibitor, and triacetyluridine, a prodrug of
 uridine)
 RN 4105-38-8 HCAPLUS
 CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Treatment of chemotherapeutic agent and antiviral agent
 toxicity with acylated pyrimidine nucleosides
 AB Compds., compns., and methods are disclosed for treatment and prevention
 of toxicity due to chemotherapeutic agents and
 antiviral agents. Disclosed are acylated derivs. of nonmethylated
 pyrimidine nucleosides. These compds. are capable of attenuating damage
 to the hematopoietic system in animals receiving antiviral or
 antineoplastic chemotherapy.


AN 1999:670113 HCAPLUS <<LOGINID::20081217>>
 DN 131:281604
 TI Treatment of chemotherapeutic agent and antiviral agent
 toxicity with acylated pyrimidine nucleosides
 IN Von Borstel, Reid; Bamat, Michael K.
 PA Pro-Neuron, Inc., USA
 SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5968914	A	19991019	US 1995-472210	19950607
	EP 712629	A1	19960522	EP 1995-203050	19881027
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027
	CA 2111571	A1	19930121	CA 1992-2111571	19920625
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625
	ZA 9204975	A	19930428	ZA 1992-4975	19920703
	IN 175688	A1	19950812	IN 1992-CA473	19920706
	US 5246708	A	19930921	US 1992-911379	19920713
	US 5470838	A	19951128	US 1992-997657	19921230
	US 5583117	A	19961210	US 1993-140475	19931025
	US 6020320	A	20000201	US 1993-153163	19931117
	US 5736531	A	19980407	US 1993-176485	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	US 5770582	A	19980623	US 1995-419767	19950410
	US 5691320	A	19971125	US 1995-465454	19950605
	US 6054441	A	20000425	US 1995-463790	19950605
	US 6060459	A	20000509	US 1995-465016	19950605
	US 7307166	B1	20071211	US 1995-463771	19950605
	US 6258795	B1	20010710	US 1995-466145	19950606
	US 6316426	B1	20011113	US 1995-466144	19950606
	US 6232298	B1	20010515	US 1995-479519	19950607
	US 6274563	B1	20010814	US 1995-479349	19950607
	US 6348451	B1	20020219	US 1995-478736	19950607
	US 6919320	B1	20050719	US 1995-473331	19950607
	CA 2223640	A1	19961219	CA 1996-2223640	19960606
	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1192149	A	19980902	CN 1996-195929	19960606
	JP 10511689	T	19981110	JP 1997-502184	19960606
	JP 2003201240	A	20030718	JP 2003-721	19960606
	EP 1491201	A1	20041229	EP 2004-23557	19960606

EP	1491201	B1	20060322		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL				
AT	320813	T	20060415	AT	2004-23557 19960606
ES	2257721	T3	20060801	ES	2004-23557 19960606
PT	1491201	T	20060831	PT	2004-23557 19960606
HK	1072897	A1	20060512	HK	2005-105421 19981003
US	20010025032	A1	20010927	US	1999-249790 19990216
US	6344447	B2	20020205		
AU	9952624	A	19991202	AU	1999-52624 19991001
US	6743782	B1	20040601	US	2000-494242 20000131
AU	2002320811	A1	20030403	AU	2002-320811 20021223
US	20040033981	A1	20040219	US	2003-601863 20030624
US	20040192635	A1	20040930	US	2004-824501 20040415
US	20040220134	A1	20041104	US	2004-855835 20040528
AU	2005232288	A1	20051201	AU	2005-232288 20051110
JP	2006137772	A	20060601	JP	2005-380457 20051228
JP	2008019268	A	20080131	JP	2007-233452 20070907
PRAI	US 1987-115923	B2	19871028		
	US 1987-115929	B2	19871028		
	US 1989-438493	B2	19890627		
	US 1990-487984	B2	19900205		
	US 1991-724340	B2	19910705		
	US 1992-903107	B2	19920625		
	US 1993-61381	B2	19930514		
	US 1993-176485	A2	19931230		
	US 1988-186031	B2	19880425		
	EP 1988-910239	A3	19881027		
	JP 1988-509176	A3	19881027		
	JP 1994-303877	A3	19881027		
	JP 2000-379524	A3	19881027		
	US 1989-341925	B1	19890421		
	US 1990-533933	B1	19900605		
	US 1990-438493	B2	19900626		
	US 1991-653882	B2	19910208		
	US 1991-737913	B3	19910729		
	CA 1992-2111571	A3	19920625		
	IN 1992-CA473	A1	19920706		
	US 1992-911379	A3	19920713		
	US 1992-925931	B2	19920807		
	US 1992-958598	B3	19921007		
	US 1992-987730	B2	19921208		
	US 1992-997657	A3	19921230		
	US 1993-96407	B1	19930726		
	US 1993-98884	B1	19930729		
	US 1993-153163	A1	19931117		
	US 1993-158799	B2	19931201		
	US 1994-266897	B3	19940701		
	US 1994-289214	A3	19940812		
	US 1995-419767	A3	19950410		
	US 1995-463740	A1	19950605		
	US 1995-472210	A	19950607		
	AU 1995-29150	A3	19950630		
	EP 1996-918461	A3	19960606		
	JP 1997-502184	A3	19960606		
	WO 1996-US10067	W	19960606		
	HK 1998-111095	A3	19981003		
	AU 1999-52624	A3	19991001		
	US 2000-494242	A3	20000131		
	AU 2002-320811	A3	20021223		
	JP 2005-380457	A3	20051228		


IT 4105-38-8 56787-28-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides)
 RN 4105-38-8 HCAPLUS
 CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 56787-28-1 HCAPLUS
 CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
 AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.
 AN 1997:141015 HCAPLUS <<LOGINID::20081217>>
 DN 126:139905
 OREF 126:26891a
 TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
 IN Vonborstel, Reid W.; Bamat, Michael K.
 PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	US 5968914	A	19991019	US 1995-472210	19950607
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 10511689	T	19981110	JP 1997-502184	19960606
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1995-472210	A	19950607		
	US 1987-115923	B2	19871028		
	US 1987-115929	B2	19871028		
	US 1989-438493	B2	19890627		
	US 1990-487984	B2	19900205		
	US 1991-724340	B2	19910705		
	US 1992-903107	B2	19920625		
	IN 1992-CA473	A1	19920706		
	US 1993-61381	B2	19930514		
	US 1993-176485	A2	19931230		
	AU 1995-29150	A3	19950630		
	WO 1996-US10067	W	19960606		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
IT	4105-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(acylated pyrimidine nucleosides, alone or in combination with other compds., for reducing toxicity of chemotherapeutic and antiviral agents)				
RN	4105-38-8	HCAPLUS			
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.



IT 56787-28-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acylated pyrimidine nucleosides, alone or in combination with other
 compds., for reducing toxicity of chemotherapeutic
 and antiviral agents)
 RN 56787-28-1 HCAPLUS
 CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Pyrimidine nucleotide precursors for treatment of systemic inflammation
 and inflammatory hepatitis
 AB Pyrimidine nucleotide precursors, including acyl derivs. of cytidine,
 uridine, and orotate, and uridine phosphorylase
 inhibitors, and their use in enhancing resistance to sepsis or systemic
 inflammation, are disclosed. Triacetyluridine improved survival of mice
 treated with a LD of Salmonella typhimurium endotoxin, reduced
 endotoxin-caused tissue damage, reduced mortality in viral hepatitis in
 mice, and improved recovery from ethanol intoxication.
 AN 1996:205056 HCAPLUS <<LOGINID::20081217>>
 DN 124:250921
 OREF 124:46221a,46224a
 TI Pyrimidine nucleotide precursors for treatment of systemic inflammation
 and inflammatory hepatitis
 IN Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.
 PA Pro-Neuron, Inc., USA
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9601115	A1	19960118	WO 1995-US8259	19950630
	W: AU, CA, CN, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IN	177670	A1	19970215	IN 1994-CA701	19940902
US	5691320	A	19971125	US 1995-465454	19950605
US	6232298	B1	20010515	US 1995-479519	19950607
CA	2193967	A1	19960118	CA 1995-2193967	19950630
CA	2193967	C	20070911		
AU	9529150	A	19960125	AU 1995-29150	19950630
AU	712679	B2	19991111		
EP	768883	A1	19970423	EP 1995-924764	19950630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN	1156409	A	19970806	CN 1995-194806	19950630
JP	10505578	T	19980602	JP 1996-503935	19950630

	CN 101066276	A	20071107	CN 2006-10105555	19950630
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	US 20030212036	A1	20031113	US 2003-421831	20030424
	US 20040033981	A1	20040219	US 2003-601863	20030624
	US 20040220134	A1	20041104	US 2004-855835	20040528
	AU 2005232281	A1	20051201	AU 2005-232281	20051110
	AU 2005232286	A1	20051201	AU 2005-232286	20051110
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
	JP 2008007525	A	20080117	JP 2007-250303	20070926
PRAI	US 1994-266897	A	19940701		
	US 1987-115929	B2	19871028		
	US 1989-438493	B2	19890627		
	US 1990-438493	B2	19900626		
	IN 1992-CA473	A1	19920706		
	US 1992-987730	B2	19921208		
	US 1993-158799	B2	19931201		
	US 1995-463740	A1	19950605		
	US 1995-479519	A1	19950607		
	AU 1995-29150	A3	19950630		
	CN 1995-194806	A3	19950630		
	JP 1996-503935	A3	19950630		
	WO 1995-US8259	W	19950630		
	AU 1999-52624	A3	19991001		
	US 2000-702876	A3	20001101		
	AU 2002-320811	A3	20021223		
IT	4105-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis)				
RN	4105-38-8	HCAPLUS			
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.



L15 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents

AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Effects of other derivs. are also presented. Synthesis of ethoxycarbonyluridine is included.

AN 1995:756200 HCAPLUS <<LOGINID::20081217>>

DN 123:160865

OREF 123:28387a

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

IN Von Borstel, Reid Warren; Bamat, Michael Kevin

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514		
	IN 1992-CA473	A1	19920706		
	WO 1993-US12689	W	19931230		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		

OS MARPAT 123:160865

IT 4105-38-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)

(acylated pyrimidine nucleosides for treatment of toxicity
from chemotherapeutic and antiviral agents)

RN 4105-38-8 HCAPLUS

CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.




IT 56787-28-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acylated pyrimidine nucleosides for treatment of toxicity
from chemotherapeutic and antiviral agents)

RN 56787-28-1 HCAPLUS

CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



=> s 113 and (PY<1994 or AY<1994 or PRY<1994)

15527045 PY<1994

2751634 AY<1994

2193143 PRY<1994

L16 43 L13 AND (PY<1994 OR AY<1994 OR PRY<1994)

=> d 116 1-43 ti abs bib hitstr

L16 ANSWER 1 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

AB Compds., compns., and methods are disclosed for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

AN 1999:670113 HCAPLUS <<LOGINID::20081217>>

DN 131:281604

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

IN Von Borstel, Reid; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5968914	A	19991019	US 1995-472210	19950607 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--

US 5736531	A	19980407	US 1993-176485	19931230 <--
IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
US 5770582	A	19980623	US 1995-419767	19950410 <--
US 5691320	A	19971125	US 1995-465454	19950605 <--
US 6054441	A	20000425	US 1995-463790	19950605 <--
US 6060459	A	20000509	US 1995-465016	19950605 <--
US 7307166	B1	20071211	US 1995-463771	19950605 <--
US 6258795	B1	20010710	US 1995-466145	19950606 <--
US 6316426	B1	20011113	US 1995-466144	19950606 <--
US 6232298	B1	20010515	US 1995-479519	19950607 <--
US 6274563	B1	20010814	US 1995-479349	19950607 <--
US 6348451	B1	20020219	US 1995-478736	19950607 <--
US 6919320	B1	20050719	US 1995-473331	19950607 <--
CA 2223640	A1	19961219	CA 1996-2223640	19960606
WO 9640165	A1	19961219	WO 1996-US10067	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9661114	A	19961230	AU 1996-61114	19960606
AU 724805	B2	20000928		
EP 831849	A1	19980401	EP 1996-918461	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1192149	A	19980902	CN 1996-195929	19960606
JP 10511689	T	19981110	JP 1997-502184	19960606
JP 2003201240	A	20030718	JP 2003-721	19960606
EP 1491201	A1	20041229	EP 2004-23557	19960606
EP 1491201	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL				
AT 320813	T	20060415	AT 2004-23557	19960606
ES 2257721	T3	20060801	ES 2004-23557	19960606
PT 1491201	T	20060831	PT 2004-23557	19960606
HK 1072897	A1	20060512	HK 2005-105421	19981003
US 20010025032	A1	20010927	US 1999-249790	19990216 <--
US 6344447	B2	20020205		
AU 9952624	A	19991202	AU 1999-52624	19991001
US 6743782	B1	20040601	US 2000-494242	20000131 <--
AU 2002320811	A1	20030403	AU 2002-320811	20021223
US 20040033981	A1	20040219	US 2003-601863	20030624 <--
US 20040192635	A1	20040930	US 2004-824501	20040415 <--
US 20040220134	A1	20041104	US 2004-855835	20040528 <--
AU 2005232288	A1	20051201	AU 2005-232288	20051110
JP 2006137772	A	20060601	JP 2005-380457	20051228 <--
JP 2008019268	A	20080131	JP 2007-233452	20070907 <--
PRAI US 1987-115923	B2	19871028	<--	
US 1987-115929	B2	19871028	<--	
US 1989-438493	B2	19890627	<--	
US 1990-487984	B2	19900205	<--	
US 1991-724340	B2	19910705	<--	
US 1992-903107	B2	19920625	<--	
US 1993-61381	B2	19930514	<--	
US 1993-176485	A2	19931230	<--	
US 1988-186031	B2	19880425	<--	
EP 1988-910239	A3	19881027	<--	
JP 1988-509176	A3	19881027	<--	
JP 1994-303877	A3	19881027	<--	
JP 2000-379524	A3	19881027	<--	

US	1989-341925	B1	19890421	<--
US	1990-533933	B1	19900605	<--
US	1990-438493	B2	19900626	<--
US	1991-653882	B2	19910208	<--
US	1991-737913	B3	19910729	<--
CA	1992-2111571	A3	19920625	<--
IN	1992-CA473	A1	19920706	<--
US	1992-911379	A3	19920713	<--
US	1992-925931	B2	19920807	<--
US	1992-958598	B3	19921007	<--
US	1992-987730	B2	19921208	<--
US	1992-997657	A3	19921230	<--
US	1993-96407	B1	19930726	<--
US	1993-98884	B1	19930729	<--
US	1993-153163	A1	19931117	<--
US	1993-158799	B2	19931201	<--
US	1994-266897	B3	19940701	
US	1994-289214	A3	19940812	
US	1995-419767	A3	19950410	
US	1995-463740	A1	19950605	
US	1995-472210	A	19950607	
AU	1995-29150	A3	19950630	
EP	1996-918461	A3	19960606	
JP	1997-502184	A3	19960606	
WO	1996-US10067	W	19960606	
HK	1998-111095	A3	19981003	
AU	1999-52624	A3	19991001	
US	2000-494242	A3	20000131	
AU	2002-320811	A3	20021223	
JP	2005-380457	A3	20051228	

IT 4105-38-8 56787-28-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides)

RN 4105-38-8 HCAPLUS

CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)


Absolute stereochemistry.



RN 56787-28-1 HCAPLUS

CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions of chemotherapeutic agent or antiviral agent with
acylated pyrimidine nucleosides
AB The subject invention discloses compds., compns. and methods for treatment
and prevention of toxicity due to chemotherapeutic
agents and antiviral agents. Disclosed are acylated derivs. of
non-methylated pyrimidine nucleosides. These compds. are capable of
attenuating damage to the hematopoietic system in animals receiving
antiviral or antineoplastic chemotherapy. Thus, biol activity
of 5-fluorouracil is reported.
AN 1998:236253 HCAPLUS <<LOGINID::20081217>>
DN 128:266247
OREF 128:52559a,52562a
TI Compositions of chemotherapeutic agent or antiviral agent with
acylated pyrimidine nucleosides
IN Von Borstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5736531	A	19980407	US 1993-176485	19931230 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5770582	A	19980623	US 1995-419767	19950410 <--
	US 5691320	A	19971125	US 1995-465454	19950605 <--
	US 6054441	A	20000425	US 1995-463790	19950605 <--
	US 6060459	A	20000509	US 1995-465016	19950605 <--

	US	7307166	B1	20071211	US	1995-463771	19950605	<--
	US	6258795	B1	20010710	US	1995-466145	19950606	<--
	US	6316426	B1	20011113	US	1995-466144	19950606	<--
	US	5968914	A	19991019	US	1995-472210	19950607	<--
	US	6232298	B1	20010515	US	1995-479519	19950607	<--
	US	6274563	B1	20010814	US	1995-479349	19950607	<--
	US	6348451	B1	20020219	US	1995-478736	19950607	<--
	US	6919320	B1	20050719	US	1995-473331	19950607	<--
	US	7166581	B1	20070123	US	1995-473330	19950607	<--
	US	20010025032	A1	20010927	US	1999-249790	19990216	<--
	US	6344447	B2	20020205				
	AU	9952624	A	19991202	AU	1999-52624	19991001	
	US	6743782	B1	20040601	US	2000-494242	20000131	<--
	AU	2002320811	A1	20030403	AU	2002-320811	20021223	
	US	20040033981	A1	20040219	US	2003-601863	20030624	<--
	US	20040192635	A1	20040930	US	2004-824501	20040415	<--
	US	20040220134	A1	20041104	US	2004-855835	20040528	<--
	AU	2005232288	A1	20051201	AU	2005-232288	20051110	
	JP	2006137772	A	20060601	JP	2005-380457	20051228	<--
	JP	2008019268	A	20080131	JP	2007-233452	20070907	<--
PRAI	US	1987-115923	B2	19871028	<--			
	US	1987-115929	B2	19871028	<--			
	US	1989-438493	B2	19890627	<--			
	US	1990-487984	B2	19900205	<--			
	US	1991-724340	B2	19910705	<--			
	US	1992-903107	B2	19920625	<--			
	US	1993-61381	B2	19930514	<--			
	US	1988-186031	B2	19880425	<--			
	EP	1988-910239	A3	19881027	<--			
	JP	1988-509176	A3	19881027	<--			
	JP	1994-303877	A3	19881027	<--			
	JP	2000-379524	A3	19881027	<--			
	US	1989-341925	B1	19890421	<--			
	US	1990-533933	B1	19900605	<--			
	US	1990-438493	B2	19900626	<--			
	US	1991-653882	B2	19910208	<--			
	US	1991-737913	B3	19910729	<--			
	CA	1992-2111571	A3	19920625	<--			
	IN	1992-CA473	A1	19920706	<--			
	US	1992-911379	A3	19920713	<--			
	US	1992-925931	B2	19920807	<--			
	US	1992-958598	B3	19921007	<--			
	US	1992-987730	B2	19921208	<--			
	US	1992-997657	A3	19921230	<--			
	US	1993-96407	B1	19930726	<--			
	US	1993-98884	B1	19930729	<--			
	US	1993-153163	A1	19931117	<--			
	US	1993-158799	B2	19931201	<--			
	US	1993-176485	A2	19931230	<--			
	US	1994-266897	B3	19940701				
	US	1994-289214	A3	19940812				
	US	1995-419767	A3	19950410				
	US	1995-463740	A1	19950605				
	US	1995-472210	A1					

86996-92-1, 5'-O-Octanoyluridine 205645-75-6
205645-76-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides)

RN 4105-38-8 HCAPLUS

CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)


Absolute stereochemistry.



RN 54618-06-3 HCAPLUS

CN Uridine, 5'-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86996-92-1 HCAPLUS

CN Uridine, 5'-octanoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205645-75-6 HCAPLUS


CN Uridine, 5'-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205645-76-7 HCAPLUS
 CN Uridine, 5'-(ethyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Cytarabine derivatives, the preparation and use thereof
 AB Novel cytarabine derivs. are suitable for use directly or in the form of immunoliposomes for targeted destruction of certain tumor cells. The compds. are distinguished from AraC by improved deaminase resistance. 4-(1-Octadecylamino)- β -D-arabinofuranosyl-2(1H)-pyrimidinone (I) was prepared by treating octadecylamine with 4-(1,2,4-triazol-1-yl)-1- β -D-2',3',5'-tri-O-acetylarabinofuranosyl-2(1H)-pyrimidinone in dioxane. Leukemia was simulated in mice by i.v. injection of L1210 tumor cells; on days 3 and 7 after injection of the tumor cells, the tumor-bearing animals received various doses of I in an antibody-immobilized liposome preparation. The result of the treatment was assessed by calculating the median survival time in each of the exptl. groups; I showed a better effect than AraC.

AN 1997:425976 HCAPLUS <<LOGINID::20081217>>

DN 127:104330

OREF 127:19943a,19946a

TI Cytarabine derivatives, the preparation and use thereof

IN Kluge, Michael; Schott, Herbert

PA Germany

SO U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 133,018, abandoned.
 CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5641758	A	19970624	US 1994-335090	19941107 <--
PRAI	US 1993-133018	B2	19931110	<--	
OS	MARPAT 127:104330				
IT	158233-67-1P 158233-68-2P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cytarabine derivs. and antitumor activities thereof)

RN 158233-67-1 HCAPLUS

CN 2(1H)-Pyrimidinone, 1- β -D-arabinofuranosyl-4-(octadecylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 158233-68-2 HCAPLUS

CN 2(1H)-Pyrimidinone, 1-[5-O-(3-carboxy-1-oxopropyl)- β -D-arabinofuranosyl]-4-(octadecylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.

AN 1997:141015 HCAPLUS <<LOGINID::20081217>>

DN 126:139905

OREF 126:26891a

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides


IN Vonborstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 10511689	T	19981110	JP 1997-502184	19960606
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1995-472210	A	19950607		
	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205	<--	
	US 1991-724340	B2	19910705	<--	
	US 1992-903107	B2	19920625	<--	
	IN 1992-CA473	A1	19920706	<--	
	US 1993-61381	B2	19930514	<--	
	US 1993-176485	A2	19931230	<--	
	AU 1995-29150	A3	19950630		
	WO 1996-US10067	W	19960606		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
IT	4105-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(acylated pyrimidine nucleosides, alone or in combination with other compds., for reducing toxicity of chemotherapeutic and antiviral agents)				
RN	4105-38-8	HCAPLUS			
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.



IT 56787-28-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acylated pyrimidine nucleosides, alone or in combination with other
 compds., for reducing toxicity of chemotherapeutic
 and antiviral agents)
 RN 56787-28-1 HCAPLUS
 CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 5 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Pyrimidine nucleotide precursors for treatment of systemic inflammation
 and inflammatory hepatitis
 AB Pyrimidine nucleotide precursors, including acyl derivs. of cytidine,
 uridine, and orotate, and uridine phosphorylase inhibitors, and their use
 in enhancing resistance to sepsis or systemic inflammation, are disclosed.
 Triacetyluridine improved survival of mice treated with a LD of Salmonella
 typhimurium endotoxin, reduced endotoxin-caused tissue damage, reduced
 mortality in viral hepatitis in mice, and improved recovery from ethanol
 intoxication.
 AN 1996:205056 HCAPLUS <<LOGINID::20081217>>
 DN 124:250921
 OREF 124:46221a,46224a
 TI Pyrimidine nucleotide precursors for treatment of systemic inflammation
 and inflammatory hepatitis
 IN Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.
 PA Pro-Neuron, Inc., USA
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9601115	A1	19960118	WO 1995-US8259	19950630
	W: AU, CA, CN, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IN	177670	A1	19970215	IN 1994-CA701	19940902 <--
US	5691320	A	19971125	US 1995-465454	19950605 <--
US	6232298	B1	20010515	US 1995-479519	19950607 <--
CA	2193967	A1	19960118	CA 1995-2193967	19950630
CA	2193967	C	20070911		
AU	9529150	A	19960125	AU 1995-29150	19950630
AU	712679	B2	19991111		
EP	768883	A1	19970423	EP 1995-924764	19950630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN	1156409	A	19970806	CN 1995-194806	19950630
JP	10505578	T	19980602	JP 1996-503935	19950630

	CN 101066276	A	20071107	CN 2006-10105555	19950630
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	US 20030212036	A1	20031113	US 2003-421831	20030424
	US 20040033981	A1	20040219	US 2003-601863	20030624 <--
	US 20040220134	A1	20041104	US 2004-855835	20040528 <--
	AU 2005232281	A1	20051201	AU 2005-232281	20051110
	AU 2005232286	A1	20051201	AU 2005-232286	20051110
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
	JP 2008007525	A	20080117	JP 2007-250303	20070926
PRAI	US 1994-266897	A	19940701		
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-438493	B2	19900626	<--	
	IN 1992-CA473	A1	19920706	<--	
	US 1992-987730	B2	19921208	<--	
	US 1993-158799	B2	19931201	<--	
	US 1995-463740	A1	19950605		
	US 1995-479519	A1	19950607		
	AU 1995-29150	A3	19950630		
	CN 1995-194806	A3	19950630		
	JP 1996-503935	A3	19950630		
	WO 1995-US8259	W	19950630		
	AU 1999-52624	A3	19991001		
	US 2000-702876	A3	20001101		
	AU 2002-320811	A3	20021223		
IT	4105-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis)				
RN	4105-38-8	HCAPLUS			
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.



L16 ANSWER 6 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents

AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Effects of other derivs. are also presented. Synthesis of ethoxycarbonyluridine is included.

AN 1995:756200 HCAPLUS <<LOGINID::20081217>>

DN 123:160865

OREF 123:28387a

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

IN Von Borstel, Reid Warren; Bamat, Michael Kevin

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230 <--
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514	<--	
	IN 1992-CA473	A1	19920706	<--	
	WO 1993-US12689	W	19931230	<--	
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
OS	MARPAT 123:160865				
IT	4105-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents)				
RN	4105-38-8 HCAPLUS				
CN	Uridine, 2',3',5'-triacetate (CA INDEX NAME)				

Absolute stereochemistry.




IT 56787-28-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acylated pyrimidine nucleosides for treatment of toxicity
from chemotherapeutic and antiviral agents)


RN 56787-28-1 HCAPLUS

CN Cytidine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 7 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of N-alkylcytarabine derivatives as drugs.
 GI



AB Title compds. [I; R1 = C17-24 (double bond-containing) alkyl; R2-R4 = H, acyl, PhCO, phosphate, carboxyalkyl], were prepared Thus, 4-(1,2,4-triazol-1-yl)-1-β-D-2',3',5'-tri-O-acetylarabinofuranosyl-2(1H)-pyrimidinone in dioxane was treated with n-octadecylamine in EtOH and the mixture was refluxed 2 h to give a residue which was treated with NH3 in MeOH to give 4-(n-octadecylamino)-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone. The latter at 50 mg/kg i.v. in a liposome preparation showed a > 60 day survival time in mice injected with L1210 tumor cells, vs. 7 days for untreated controls.

AN 1994:631272 HCAPLUS <<LOGINID::20081217>>

DN 121:231272

OREF 121:42194h,42195a

TI Preparation of N-alkylcytarabine derivatives as drugs.

IN Schott, Herbert

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4304038	A1	19940818	DE 1993-4304038	19930211 <--
PRAI	DE 1993-4304038		19930211	<--	


OS MARPAT 121:231272
 IT 158233-66-0P 158233-67-1P 158233-68-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-alkylcytarabine derivs. as drugs)
 RN 158233-66-0 HCAPLUS
 CN 2(1H)-Pyrimidinone, 1- β -D-arabinofuranosyl-4-(docosylamino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 158233-67-1 HCAPLUS
 CN 2(1H)-Pyrimidinone, 1- β -D-arabinofuranosyl-4-(octadecylamino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 158233-68-2 HCAPLUS
 CN 2(1H)-Pyrimidinone, 1-[5-O-(3-carboxy-1-oxopropyl)- β -D-arabinofuranosyl]-4-(octadecylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Treatment of L1210 murine leukemia with liposome-incorporated
 N4-hexadecyl-1- β -D-arabinofuranosylcytosine
 AB N4-Alkyl-1- β -D-arabinofuranosylcytosines as lipophilic derivs. of the
 widely used antitumor drug ara-C were synthesized and incorporated into
 unilamellar liposomes. The resulting preps. yielded stable unilamellar
 liposomes with diams. ranging between 40 and 70 nm. The liposomal derivs.
 exhibited an increased antitumor effect against the murine L1210 lymphoid
 leukemia at optimal molar concns. which were 16 times lower than those
 previously reported for free ara-C. The N4-alkyl-ara-C derivs. with alkyl
 chains containing 14-16 C-atoms were highly effective against L1210 leukemia
 whereas shorter chains showed no cytostatic effects. The increased
 resistance to hydrolysis of the N4-alkyl-ara-C derivs. and the improved
 antitumor effect of the liposomal N4-acyl-ara-C prodrugs, together with
 the possibility of preparing large vols. of stable and sterile liposomes,
 hold out the prospect of more effective chemotherapy for
 leukemias.
 AN 1992:557512 HCAPLUS <<LOGINID::20081217>>
 DN 117:157512
 OREF 117:27119a,27122a
 TI Treatment of L1210 murine leukemia with liposome-incorporated
 N4-hexadecyl-1- β -D-arabinofuranosylcytosine
 AU Schwendener, R. A.; Schott, H.
 CS Dep. Intern. Med., Med. Oncol., Univ. Hosp., Zurich, CH-8091, Switz.
 SO International Journal of Cancer (1992), 51(3), 466-9
 CODEN: IJCNAW; ISSN: 0020-7136
 DT Journal
 LA English
 IT 103426-87-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antileukemic activity of, from liposomes)
 RN 103426-87-5 HCAPLUS
 CN 2(1H)-Pyrimidinone, 1- β -D-arabinofuranosyl-4-(hexadecylamino)- (CA
 INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 9 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI A study on the synthesis and biological activity of nucleoside
 chemotherapeutic agents
 AB Various 5-substituted 5'-amino-5'-deoxyuridine conjugates of amino acids,
 peptides, and penicillin G, 5'-monophosphate-fatty acid derivs. were
 prepared. 5'-Amino-5'-deoxyuridine-cyclo(Phe-Asp) and
 5'-iodo-5'-deoxyuridine-penicillin G were the most efficient compds.
 against microorganisms such as Staphylococcus aureus and L5178 murine
 lymphoma cells. 5'-Monophosphates were more active than simple uridine

derivs. suggesting that other modified nucleoside 5'-phosphates should be examined as prodrugs. The MICs of the compds. prepared are tabulated.

AN 1992:439820 HCAPLUS <<LOGINID::20081217>>

DN 117:39820

OREF 117:6839a,6842a

TI A study on the synthesis and biological activity of nucleoside chemotherapeutic agents

AU Kang, Shin Won; Kim, Kyong Hee; Shine, Jung Hee; Lee, Bong Hun; Jang, Tae Sik

CS Coll. Nat. Sci., Pusan Natl. Univ., Pusan, 609-735, S. Korea

SO Misaengmul Hakhoechi (1991), 29(6), 353-60

CODEN: MIHCAR; ISSN: 0440-2413

DT Journal


LA Korean

IT 117195-79-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 117195-79-6 HCAPLUS

CN Uridine, 5'-[3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate], [2S-(2 α ,5 α ,6 β)]-(9CI) (CA INDEX NAME)



L16 ANSWER 10 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor characteristics of the conjugate of N4-(4-carboxybutyryl)-ara-C with ethylenediamine-introduced dextran and its resistance to cytidine deaminase

AB By oxidation of dextran, and reduction of the Schiff bases formed by reaction of

the oxidized dextran with diaminoalkanes, several diaminoalkane-induced dextrans were prepared and evaluated as drug carriers. Conjugates between N4-(4-carboxybutyryl)-1- β -D-arabinofuranosylcytosine (glu-ara-C) and such drug carriers were prepared, and selected conjugates were tested in vivo, and investigated for inhibitory effects on cytidine deaminase. Ethylenediamine-introduced dextran prepared under 10% oxidation conditions was found to be most useful as a drug carrier from its chemical characteristics and toxicity evaluation in BDF1 mice. The conjugate obtained from glu-ara-C and ethylenediamine-induced dextran 2000 showed high antitumor activity, significant at the relatively low dose of 100 mg equivalent ara-C/kg, in BDF1 mice bearing L1210 leukemia cells. Glu-ara-C and the conjugate were unaffected by cytidine deaminase under conditions in which 1- β -D-arabinofuranosylcytosine was degraded rapidly to 1- β -D-arabinofuranosyluracil.


AN 1991:421691 HCAPLUS <<LOGINID::20081217>>

DN 115:21691

OREF 115:3661a,3664a

TI Antitumor characteristics of the conjugate of N4-(4-carboxybutyryl)-ara-C
 with ethylenediamine-introduced dextran and its resistance to cytidine
 deaminase
 AU Onishi, Hiraku; Pithayanukul, Pimolpan; Nagai, Tsuneji
 CS Fac. Pharm. Sci., Hoshi Univ., Tokyo, Japan
 SO Drug Design and Delivery (1990), 6(4), 273-80
 CODEN: DDDEEJ; ISSN: 0884-2884
 DT Journal
 LA English
 IT 55726-38-0D, conjugates with ethylenediamine-containing dextran
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (neoplasm inhibition by, resistance to cytidine deaminase in)
 RN 55726-38-0 HCAPLUS
 CN Pentanoic acid, 5-[(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-
 pyrimidinyl)amino]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 11 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Antiviral effect of antileukemic drugs
 N4-behenoyl-1- β -D-arabinofuranosylcytosine (BH-AC) and
 2,2'-anhydro-1- β -D-arabinofuranosylcytosine (cyclo-C) against human
 cytomegalovirus
 AB The antiviral activities of antileukemic drugs
 1- β -D-arabinofuranosylcytosine (cytarabine; Ara-C),
 2,2'-anhydro-1- β -D-arabinofuranosylcytosine (ancitabine; Cyclo-C),
 and N4-behenoyl-1- β -D-arabinofuranosylcytosine (enocitabine; BH-AC)
 were evaluated in vitro against human cytomegalovirus (HCMV) in comparison
 with those of five other antiviral drugs. Both Ara-C and Cyclo-C showed
 the strongest inhibitory effect to HCMV. BH-AC inhibited the replication
 of HCMV and depicted almost as the same dose-response curve as ganciclovir
 (DHPG). In the presence of Ara-C, Cyclo-C, or BH-AC, triphosphate forms
 of the nucleoside analogs were detected in the HCMV-infected cells, and
 synthesis of HCMV DNA was strongly suppressed. Thus, Ara-C, Cyclo-C, and
 BH-AC were not only antileukemic, but also antiviral in vitro. However,
 Ara-C and Cyclo-C may not be suitable as anti-HCMV agents, because they
 are cytotoxic or excreted rapidly in the urine in vivo. Because of lower
 toxicity and longer retention in vivo, BH-AC may be expected as an
 anti-HCMV agent in patients with leukemia, in addition to serving as an
 antileukemic drug.
 AN 1990:544907 HCAPLUS <<LOGINID::20081217>>
 DN 113:144907
 OREF 113:24397a,24400a
 TI Antiviral effect of antileukemic drugs
 N4-behenoyl-1- β -D-arabinofuranosylcytosine (BH-AC) and
 2,2'-anhydro-1- β -D-arabinofuranosylcytosine (cyclo-C) against human

cytomegalovirus
 AU Nakamura, Kazuo; Eizuru, Yoshito; Kumura, Keiko; Minamishima, Yoichi
 CS Dep. Microbiol., Miyazaki Med. Coll., Kiyotake, 889-16, Japan
 SO Journal of Medical Virology (1990), 31(2), 141-7
 CODEN: JMVIDB; ISSN: 0146-6615
 DT Journal
 LA English
 IT 55726-47-1, Enocitabine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiviral activity of, against human cytomegalovirus)
 RN 55726-47-1 HCAPLUS
 CN Docosanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 12 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia
 AB The MTT dye reduction assay was applied to the anti-cancer drug sensitivity test using short-term microplate cultures. Blast cells were cultured with approx. 25 anti-cancer drugs for 4 days. After cultivation tetrazolium-based (MTT) dye was placed in each well, and the formazans generated by living cells were dissolved in acidified iso-Pr alc. The absorbance of each well was measured at a scanning microplate photometer. Using the table of the cytotoxicity index (CI) that was classified into anti-cancer drugs and concns. for ech leukemic sample, it was possible to compare efficacy with different drugs and to select the effective ones. Retrospectively, the in vitro results were compared with the clin. responses of the 34 patients (26 of acute lymphocytic leukemia [ALL] and eight of acute nonlymphoblastic leukemia [ANLL]) who were treated by combination chemotherapy. The following results were obtained: true-pos. rate, 78.1%; true-neg. rate, 57.1%; and predictive accuracy, 74.4%. Therefore, the MTT assay-CI table might serve as a reliable tool for the selection of effective chemotherapy in patients with acute leukemia.
 AN 1990:191286 HCAPLUS <<LOGINID::20081217>>
 DN 112:191286
 OREF 112:32125a,32128a
 TI An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia
 AU Hongo, Teruaki; Fujii, Yuji; Igarashi, Yoshio
 CS Sch. Med., Hamamatsu Univ., Hamamatsu, 431-31, Japan
 SO Cancer (New York, NY, United States) (1990), 65(6), 1263-72
 CODEN: CANCAR; ISSN: 0008-543X
 DT Journal

LA English
 IT 55726-47-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antitumor activity of, screening of, in childhood leukemia culture with formazan chemosensitivity)
 RN 55726-47-1 HCAPLUS
 CN Docosanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 13 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Liposomal sustained-release delivery systems for intravenous injection.
 IV. Antitumor activity of newly synthesized lipophilic 1- β -D-arabinofuranosylcytosine prodrug-bearing liposomes
 AB A lipophilic prodrug of 1- β -D-arabinofuranosylcytosine (Ara-C), namely N4-[N-(cholesteryloxycarbonyl)glycyl]-Ara-C (COCG-Ara-C), was synthesized, and its antitumor activity in a liposome-entrapped form was studied. COCG-Ara-C showed an increased lipophilicity and almost complete entrapment in liposomes. COCG-Ara-C was hydrolyzed to the parent drug chemical, but the hydrolysis was accelerated in the presence of mouse, rat, and human plasma. The in vitro cytotoxicity of the prodrug against P 388 leukemia was approx. one-fifth that of Ara-C and 4 times that of N4-behenoyl-Ara-C (BHAC). For in vivo antitumor activity tests, unilamellar vesicles composed of egg phosphatidylcholine (PC), egg sphingomyelin (SM) and COCG-Ara-C in a molar ratio of 7:3:X (X = 0-2.0) were prepared by the combination of controlled dialysis and sequential extrusion. The vesicle size ranged from 108 to 124 nm. In all the antitumor activity studies, chemotherapy was performed i.v. The antitumor activity of COCG-Ara-C-bearing liposomes against i.p. or i.v. inoculated mouse L 1210 leukemia was clearly superior to those of Ara-C and BHAC aqueous solns. The efficacy of COCG-Ara-C against L 1210 leukemia was dependent upon the dosage form: regardless of implantation route, liposomal COCG-Ara-C showed a more potent activity than free COCG-Ara-C (aqueous solution). Prodrug-bearing liposomes also inhibited the growth of a human lung adenocarcinoma A 549 xenograft implanted under the renal capsule more efficiently than did Ara-C and BHAC aqueous solns. These results suggest the potential usefulness of COCG-Ara-C-bearing liposomes in cancer chemotherapy.
 AN 1989:18186 HCAPLUS <<LOGINID::20081217>>
 DN 110:18186
 OREF 110:2989a,2992a
 TI Liposomal sustained-release delivery systems for intravenous injection.
 IV. Antitumor activity of newly synthesized lipophilic 1- β -D-arabinofuranosylcytosine prodrug-bearing liposomes
 AU Tokunaga, Yuji; Iwasa, Tomoaki; Fujisaki, Jiro; Sawai, Seiji; Kagayama,

Akira
 CS Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Tsukuba, 300-26, Japan
 SO Chemical & Pharmaceutical Bulletin (1988), 36(9), 3574-83
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 IT 112548-60-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antitumor activity of)
 RN 112548-60-4 HCAPLUS
 CN Cholest-5-en-3-ol (3 β)-, [2-[(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethyl]carbamate (9CI) (CA INDEX NAME)

L16 ANSWER 14 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside
 GI



AB Lipophilic N1-acetyl and N4-chloroacetyl derivs. (I, R = H, ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H or Cl) of cytidine, 2'-deoxycytidine and cytosine arabinoside (Ara-C) were prepared by acetylation and chloroacetylation, resp. Their toxicity to A(Ti)Cl-3 hamster fibrosarcoma cells was determined I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = Cl) were potent with no colonies surviving at concns. of 10-4, 10-4, and 10-6M, resp. I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H) showed comparatively poor toxicity with 95, 77 and 87% survival of colonies, resp. N4-Chloroacetyl-2'-deoxycytidine and N4-chloroacetyl-Ara-C underwent hydrolysis in phosphate-buffered saline at 50° to yield the parent nucleosides and the N3-carboxymethyl derivs. via 1-H-2,3-dihydro-2,5-dioxoimidazo[1,2-c]pyrimidines.

AN 1988:142952 HCAPLUS <<LOGINID::20081217>>

DN 108:142952

OREF 108:23279a,23282a

TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside

AU Ariatti, Mario; Jones, Peter A.

CS Dep. Biochem., Univ. Durban-Westville, Durban, 4000, S. Afr.

SO Biochemistry International (1987), 15(6), 1097-103

CODEN: BIINDF; ISSN: 0158-5231

DT Journal


LA English

IT 3768-18-1P 13491-47-9P 113737-50-1P
 113737-52-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic

use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antitumor activity of)
 RN 3768-18-1 HCAPLUS
 CN Cytidine, N-acetyl- (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 15 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Enocitabine (Sunrabin): an antitumor agent
 GI



I


AB A review, with 9 refs., of the antitumor activity and related pharmacol.
 of enocitabine (I) [55726-47-1].
 AN 1986:417659 HCAPLUS <<LOGINID::20081217>>
 DN 105:17659
 OREF 105:2805a,2808a
 TI Enocitabine (Sunrabin): an antitumor agent
 AU Tsukagoshi, S.
 CS Cancer Chemotherapy Cent., Cancer Inst., Tokyo, 170, Japan
 SO Drugs of Today (1986), 22(4), 169-74
 CODEN: MDACAP; ISSN: 0025-7656
 DT Journal; General Review
 LA English
 IT 55726-47-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (neoplasm inhibition by, in humans and laboratory animals)
 RN 55726-47-1 HCAPLUS
 CN Docosanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-
 pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 16 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Experimental study on the correlation between antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC)
AB BH-AC [55726-47-1] (i.p. or i.v.) had a better antitumor effect than Ara-C [147-94-4] in mice implanted with L1210 leukemia cells (i.p., i.v., or s.c.). Neither the route of Ara-C administration nor the route of tumor implantation had any bearing on its antitumor effect; however, with BH-AC, the activity was dependent on the route of administration of both BH-AC and the tumor cells. Detectable concns. of BH-AC lasted longer than those of Ara-C in the ascitic fluid, plasma, and tumor, suggesting that the superior antitumor effect of BH-AC is closely related to its longer retention in the tumor tissue.
AN 1986:218749 HCAPLUS <<LOGINID::20081217>>
DN 104:218749
OREF 104:34505a,34508a
TI Experimental study on the correlation between antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC)
AU Takenaka, Takeaki; Kimura, Kiyoji
CS Dep. Intern. Med., Natl. Cancer Cent. Hosp., Japan
SO Nippon Gan Chiryo Gakkaishi (1985), 20(10), 2322-8
CODEN: NGCJAK; ISSN: 0021-4671
DT Journal
LA Japanese
IT 55726-47-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by, pharmacokinetics in relation to)
RN 55726-47-1 HCAPLUS
CN Docosanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 17 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Antitumor activity and pharmacological fate of N4-palmitoyl-ara-C after oral administration
 AB N4-Palmitoyl-ara-C (I) [55726-45-9] was more active than ara-C [147-94-4] against several murine tumors after oral administration; I slowly released ara-C over a long period of time. Following oral administration of [14C]I, the main radioactive metabolites in plasma and tissues were ara-C and ara-U [3083-77-0]. The potent antitumor activity of I is probably partly related to the sustained plasma ara-C levels after oral administration.
 AN 1986:14593 HCAPLUS <<LOGINID::20081217>>
 DN 104:14593
 OREF 104:2373a,2376a
 TI Antitumor activity and pharmacological fate of N4-palmitoyl-ara-C after oral administration
 AU Tsukagoshi, Shigeru; Tsuruo, Takashi; Sakurai, Yoshio
 CS Div. Exp. Chemother., Cancer Chemother. Cent., Tokyo, 170, Japan
 SO Proc. Int. Congr. Chemother., 13th (1983), Volume 17, 286/81-286/84. Editor(s): Spitzzy, K. H.; Karrer, K. Publisher: Verlag H. Egermann, Vienna, Austria.
 CODEN: 53XPA8
 DT Conference
 LA English
 IT 55726-45-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neoplasm inhibition by, pharmacokinetics in relation to)
 RN 55726-45-9 HCAPLUS
 CN Hexadecanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 18 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor effects of 1- β -D-arabinofuranosylcytosine conjugates of
 1,2-dipalmitins on L1210 leukemia in mice
 GI



AB Antitumor activities of 1- β -D-arabinofuranosylcytosine
 5'-diphosphate-L-1,2-dipalmitin (ara-CDP-L-dipalmitin) (I) [71065-86-6]
 and its stereoisomer ara-CDP-D-dipalmitin [92693-06-6] and
 ara-CDP-DL-dipalmitin [63357-80-2] were compared in mice inoculated with
 L1210 lymphoid leukemia. The order of antitumor activity was L > D > DL.
 The difference between the L- and the DL-isomers was particularly apparent
 on the advanced state of the diseases. In mice implanted with ara-C
 [147-94-4]-resistant L1210 leukemia, the L-isomer gave a marked increase
 of life span, but the D-isomer was ineffective. Thus, the best conjugates
 of this type have a linkage with the naturally occurring phospholipid.

AN 1985:605547 HCAPLUS <<LOGINID::20081217>>

DN 103:205547

OREF 103:32977a,32980a

TI Antitumor effects of 1- β -D-arabinofuranosylcytosine conjugates of
 1,2-dipalmitins on L1210 leukemia in mice

AU Hong, Chung I.; An, S. H.; Nechaev, A.; Buchheit, D. J.; West, C. R.;
 MacCoss, Malcolm

CS Dep. Neurosurg., Roswell Park Mem. Inst., Buffalo, NY, 14263, USA

SO Proc. Int. Congr. Chemother., 13th (1983), Volume 16,
 257/19-257/22. Editor(s): Spitzzy, K. H.; Karrer, K. Publisher: Verlag H.
 Egermann, Vienna, Austria.

CODEN: 53XPA8

DT Conference

LA English

IT 31088-06-9 55726-45-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)

(neoplasm inhibition by)

RN 31088-06-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)- β -D-
 arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 55726-45-9 HCAPLUS


CN Hexadecanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 19 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Enhancement of antitumor activity of cytosine arabinoside by hydroxyurea
GI



I

AB Antitumor activity of cytosine arabinoside (I) [147-94-4] or its derivative is enhanced in the presence of hydroxyurea [127-07-1]. Thus, the antitumor activity of I was demonstrated in mice i.p. receiving I (20 .apprx.56 mg/kg) and hydroxyurea (53 .apprx.210 mg/kg) twice a day for 7 days, starting the 2nd day after i.p. implantation of leukemia L-1210 cells.

AN 1985:516285 HCAPLUS <<LOGINID::20081217>>

DN 103:116285

OREF 103:18469a,18472a

TI Enhancement of antitumor activity of cytosine arabinoside by hydroxyurea

PA Sato, Haruo, Japan


SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 60089423	A	19850520	JP 1983-198718	19831024 <--
PRAI	JP 1983-198718		19831024	<--	
IT	55726-47-1				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(antitumor activity of, hydroxyurea enhancement of)				
RN	55726-47-1	HCAPLUS			
CN	Docosanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)				

Absolute stereochemistry.



L16 ANSWER 20 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Screening test of antitumor agents by human tumor cell lines in nude mice in ascitic form

AB Human breast cancer and leukemic cells implanted in nude mice appeared to be useful models for the screening of neoplasm inhibitors. The sensitivities of implanted tissues to drugs were similar to those found in patients. Studies on the suitable route of administration in these mice provide the best administration routes for humans.

AN 1985:17008 HCAPLUS <<LOGINID::20081217>>

DN 102:17008

OREF 102:2685a,2688a

TI Screening test of antitumor agents by human tumor cell lines in nude mice in ascitic form

AU Kitahara, Takeshi; Minato, Keisuke; Shimoyama, Masanori

CS Natl. Cancer Cent. Hosp., Japan

SO Gan no Rinsho (1984), 30(9), 1158-67

CODEN: GANRAE; ISSN: 0021-4949

DT Journal

LA Japanese

IT 55726-45-9 55726-47-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of, against human tumor xenografts in nude mice)

RN 55726-45-9 HCAPLUS


CN Hexadecanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 55726-47-1 HCAPLUS
CN Docosanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 21 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Platinum-dioxypyrimidine complexes
AB Complexes of 2,4-dioxypyrimidines with cis-diaquodiamineplatinum (II) were prepared and tested for antitumor, antibacterial and antiviral activity. The complexes appear to have good activity with low renal toxicity
AN 1984:114992 HCAPLUS <<LOGINID::20081217>>
DN 100:114992
OREF 100:17361a,17364a
TI Platinum-dioxypyrimidine complexes
IN Rosenberg, Barnett; Van Camp, Loretta; Ficher, Robert G.; Kansy, Samir; Peresie, Henry J.; Davidson, James P.
PA Research Corp. , USA
SO U.S., 11 pp. Cont. of U.S. Ser. No. 803,269, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4419351	A	19831206	US 1978-970524	19781218 <--
PRAI	US 1974-508854	A1	19740924	<--	
	US 1977-803269	A1	19770603	<--	
OS	MARPAT 100:114992				
IT	1748-04-5D, platinum complexes				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological				


study); USES (Uses)
 (neoplasm-inhibiting activity of)
 RN 1748-04-5 HCAPLUS
 CN Uridine, 2',3',5'-tribenzoate (CA INDEX NAME)

Absolute stereochemistry.




IT 4105-38-8DP, platinum complexes
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and neoplasm-inhibiting activity of)
 RN 4105-38-8 HCAPLUS
 CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 22 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Has the well gone dry? The first Cain Memorial Award Lecture
 GI



AB The development of 2-halo adenine arabinonucleosides as potential antitumor agents is described; data on the inhibitory action of 2-fluoro-9- β -D-arabinofuranosyladenine (I) [21679-14-1] are given and compared with those for the combined drugs ara-A [5536-17-4] and 2'-deoxycoformycin [53910-25-1]. Data are also given for the inhibition of nucleoside diphosphate reductase [9047-64-7] and DNA polymerase [9012-90-2] by 2-fluoro-ara-ATP [74832-57-8] and ara-ATP [3714-60-1].

AN 1982:592803 HCAPLUS <<LOGINID::20081217>>

DN 97:192803

OREF 97:32089a,32092a

TI Has the well gone dry? The first Cain Memorial Award Lecture

AU Montgomery, John A.

CS Kettering-Meyer Lab., South. Res. Inst., Birmingham, AL, 35255, USA

SO Cancer Research (1982), 42(10), 3911-17

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

IT 31088-06-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibition by)

RN 31088-06-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 23 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor formulations containing acylcytosine arabinosides

GI



I

AB Antitumor formulations containing N4-acylcytosine arabinosides are stabilized by fatty acid monoglycerides and fatty acid sucrose esters. For example, N4-stearoylcytosine arabinoside (I) [55726-44-8] 10, fatty acid sucrose ester 5, and stearic acid monoglyceride [31566-31-1] 2.5 g were mixed and made into powders. The product was stable when stored at 50° for 3 mo.

AN 1982:149159 HCAPLUS <<LOGINID::20081217>>

DN 96:149159

OREF 96:24441a,24444a

TI Antitumor formulations containing acylcytosine arabinosides

PA Asahi Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56145223	A	19811111	JP 1980-48931	19800414 <--
	JP 58010366	B	19830225		
PRAI	JP 1980-48931	A	19800414	<--	

IT 55726-29-9 55726-30-2 55726-32-4

55726-36-8 55726-39-1 55726-40-4

55726-42-6 55726-43-7 55726-44-8

55726-45-9 55726-46-0 55726-47-1

55726-49-3 55726-50-6 55726-52-8

55726-53-9 55726-54-0 59252-35-6

59252-37-8 59252-39-0 59252-41-4

59252-46-9 59269-59-9 60453-38-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor formulations containing, monoglycerides and sucrose fatty acid esters for stabilization of)


RN 55726-29-9 HCAPLUS

CN Butanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

L16 ANSWER 24 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Pharmaceutical preparation containing N4-acylcytosine arabinosides

GI



I

AB A storage-stable neoplasm inhibitor contains an N4-acylcytosine arabinoside (C3-24 acyl) 100, monoglyceride of a C12-18 fatty acid 10-100, and(or) a nonionic surfactant with polyoxyethylene side chains 5-500 parts by weight A mixture of 10 g N4-stearoylcytosine arabinoside (I) [55726-44-8] with varying amts. of monostearin [31566-31-1] and MYS-40 (polyoxyethylene stearate) [9004-99-3] was dissolved in EtOH at 50°, evaporated powdered, part of the powder was stored at 50° for 3 mo and part was dispersed in H2O (30 mg/mL) and tested in mice inoculated with L-1210 leukemia cells, and the percentage survival of treated/control mice was determined The mixture of 10 g I with 2.5 g monostearin

and 1 g MYS-40 had 99.8% retention of I after 3 mo at 50°, and the survival percentage was 183.

AN 1981:430401 HCAPLUS <<LOGINID::20081217>>

DN 95:30401

OREF 95:5173a,5176a

TI Pharmaceutical preparation containing N4-acylcytosine arabinosides

IN Nishimura, Daikichi; Tanimura, Noboru; Sugawara, Toshiaki; Suzuki, Nobuyuki; Ogata, Kazuyuki; Ikegawa, Akira

PA Asahi Chemical Industry Co., Ltd., Japan

SO Ger. Offen., 30 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 3033814	A1	19810326	DE 1980-3033814	19800909 <--
	DE 3033814	C2	19831027		
	JP 56040606	A	19810416	JP 1979-116607	19790911 <--
	JP 56040607	A	19810416	JP 1979-117607	19790912 <--
	JP 57034245	B	19820722		
	JP 56055309	A	19810515	JP 1979-131188	19791011 <--
	JP 57034246	B	19820722		
	BE 885161	A2	19810310	BE 1980-58740	19800910 <--
	DK 8003845	A	19810312	DK 1980-3845	19800910 <--
	DK 161491	B	19910715		
	DK 161491	C	19920106		
	NO 8002688	A	19810312	NO 1980-2688	19800910 <--
	NO 155088	B	19861103		
	NO 155088	C	19870211		
	NL 8005102	A	19810313	NL 1980-5102	19800910 <--
	NL 187727	B	19910801		
	NL 187727	C	19920102		

PRAI JP 1979-116607 A 19790911 <--
 JP 1979-117607 A 19790912 <--
 JP 1979-131188 A 19791011 <--
 OS MARPAT 95:30401
 IT 55726-29-9 55726-30-2 55726-32-4
 55726-36-8 55726-39-1 55726-40-4
 55726-41-5 55726-42-6 55726-43-7
 55726-44-8 55726-45-9 55726-46-0
 55726-47-1 55726-48-2 55726-49-3
 55726-50-6 55726-52-8 55726-53-9
 55726-54-0 59252-35-6 59252-37-8
 59252-39-0 59252-41-4 59269-59-9
 60453-38-5 60453-45-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neoplasm inhibitor, stabilization of)
 RN 55726-29-9 HCAPLUS
 CN Butanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

L16 ANSWER 25 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI N4-acylcytosine arabinosides as antitumor agents
 GI



I


AB Acylcytosine arabinosides incorporated into ribosomes (lecithins and egg-yolk lecithins) in the presence of cholesterol [57-88-5] are antitumor agents. Thus, egg-yolk lecithins 40, cholesterol 30, and N4-myristoylcytosine arabinoside (I) [55726-43-7] 8 μ mol were dissolved, resp., in 1, 2, and 0.4 mL CHCl_3 -MeOH (2:1) mixture, and these solns. were combined in a 100-mL flask, and the solvent was removed. A film produced on the inner wall of the flask was further dried in vacuum for 3 h and then dissolved in 4 mL of saline. I.p. injection of this product (I 20 μ g/kg) into mice bearing L-1210 leukemia cells increased the animal's survival rate 81%.

AN 1981:197561 HCAPLUS <<LOGINID::20081217>>
 DN 94:197561
 OREF 94:32259a,32262a
 TI N4-acylcytosine arabinosides as antitumor agents
 PA Asahi Chemical Industry Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	JP 56022724	A	19810303	JP 1979-98075	19790802 <--
	JP 57015087	B	19820329		
	US 4330534	A	19820518	US 1980-169422	19800716 <--
	GB 2055578	A	19810311	GB 1980-24259	19800724 <--
	FR 2468365	A1	19810508	FR 1980-16995	19800731 <--
	FR 2468365	B1	19830701		
PRAI	JP 1979-98075	A	19790802	<--	
OS	MARPAT 94:197561				
IT	55726-29-9 55726-36-8 55726-39-1				
	55726-41-5 55726-42-6 55726-43-7				
	55726-44-8 55726-45-9 55726-46-0				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(neoplasm inhibitor, liposomes containing)				
RN	55726-29-9 HCAPLUS				
CN	Butanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)				

L16 ANSWER 26 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Acylcytosine arabinoside formulations for neoplasm inhibition
GI



AB Effective antitumor formulations of N4-acylcytosinearabinosides are prepared with anionic surfactants and sucrose high-member fatty acid esters. These formulations are readily dispersible in water and produce a long-lasting antitumor activity in mice. Thus, N4-behenoylcytosine arabinoside (I) [55726-47-1] (1g), Na lauryl sulfate [151-21-3] (1g), and sucrose fatty acid ester (0.5g) were dissolved in 200 mL EtOH at 50°, and subsequently EtOH was evaporated out to obtain a dried solid. It was pulverized and dispersed in water in such a way to obtain 30 mg I/mL. Intragastric administration of 400 mg I to mice bearing leukemia L-1210 cells (105 cells) on the 2nd, 5th, and 7th day after the L-1210 cell inoculation increased the survival days >200% over the mean survival days of controls.

AN 1981:162789 HCAPLUS <<LOGINID::20081217>>
DN 94:162789
OREF 94:26511a,26514a
TI Acylcytosine arabinoside formulations for neoplasm inhibition
PA Asahi Chemical Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 56016408	A	19810217	JP 1979-90946	19790719 <--
PRAI	JP 1979-90946	A	19790719	<--	
IT	55726-43-7P 55726-44-8P 55726-45-9P 55726-46-0P 55726-47-1P 59269-59-9P 60453-38-5P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (antitumor formulation of, sucrose fatty acid esters and surfactants in)				
RN	55726-43-7 HCAPLUS				
CN	Tetradecanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4- pyrimidinyl)- (CA INDEX NAME)				

L16 ANSWER 27 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI N4-Palmitoyl- and N4-steroyl-1- β -D-arabinofuranosylcytosine as new
antitumor agents

GI



I, R=CO(CH₂)₁₄Me

II, R=CO(CH₂)₁₆Me

AB N4-Palmitoyl-1- β -D-arabinofuranosylcytosine (I) [55726-45-9] at 400
mg/kg orally and N4-stearoyl-1- β -D-arabinofuranosylcytosine (II)
[55726-44-8] at 800 mg/kg orally gave 150 and 130% increases, resp., in
the lifespan of mice inoculated i.p. with 105 L1210 leukemia cells.
Reabsorbed drugs were found mainly in the liver and lung. I was not
degraded to a significant extent by cultured KB cells.

AN 1980:461466 HCAPLUS <<LOGINID::20081217>>

DN 93:61466

OREF 93:9883a,9886a

TI N4-Palmitoyl- and N4-steroyl-1- β -D-arabinofuranosylcytosine as new
antitumor agents

AU Tsuruo, Takashi; Tsukagoshi, Shigeru; Sakurai, Yoshio

CS Cancer Chemother. Cent., Jap. Found. Cancer Res., Tokyo, Japan


SO Curr. Chemother. Infect. Dis., Proc. Int. Congr. Chemother., 11th (
1980), Meeting Date 1979, Volume 2, 1591-3. Editor(s): Nelson,
John D.; Grassi, Carlo. Publisher: Am. Soc. Microbiol., Washington, D. C.
CODEN: 43MKAT

DT Conference

LA English


IT 55726-44-8 55726-45-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neoplasm inhibition by)
 RN 55726-44-8 HCAPLUS
 CN Octadecanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 55726-45-9 HCAPLUS
 CN Hexadecanamide, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 28 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate
 GI



AB Cytosine arabinoside-agarose conjugate (I) [69898-92-6], obtained by covalent coupling of cytosine arabinoside (II) [147-94-4] to agarose beads, prolonged the release of I both in vivo and in vitro. I administered to mice 3 days prior to or 1 day after inoculation with L1210 cells increased the lifespan by maintaining high levels of II in the body for prolonged periods of time. Therefore, I may be used advantageously as an injectable implant for maintaining local therapeutic potency.

AN 1979:197514 HCAPLUS <<LOGINID::20081217>>

DN 90:197514

OREF 90:31279a,31282a

TI Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate

AU Hashida, Mitsuru; Kojima, Takumi; Muranishi, Shozo; Sezaki, Hitoshi

CS Fac. Pharm. Sci., Kyoto Univ., Kyoto, Japan

SO Gann (1978), 69(6), 839-43

CODEN: GANNA2; ISSN: 0016-450X

DT Journal

LA English

IT 69898-92-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibition by, prolonged release in relation to)


RN 69898-92-6 HCAPLUS

CN Agarose, (1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)carbamimidate (9CI) (CA INDEX NAME)

CM 1

CRN 172963-26-7

CMF C10 H14 N4 O6



CM 2

CRN 9012-36-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L16 ANSWER 29 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate

GI



AB The pharmaceutical and pharmacol. characteristics of a prolonged-release derivative of cytosine arabinoside (I), I-agarose bead conjugate (I-AB), were examined. I was released for long periods from I-AB, radioactivity could be detected in plasma and urine of mice for 4 days, while ³H-I administered in the free form, was excreted completely in the 1st 24 h. The lifespan of L1210 leukemia-bearing mice increased after i.p. injection of I-AB with both dosage schedules of 3 days before and 1 day after inoculation of L1210 cells at 30 mg equivalent I/kg.

AN 1979:145769 HCAPLUS <<LOGINID::20081217>>

DN 90:145769

OREF 90:23053a,23056a

TI Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate

AU Hashida, Mitsuru; Kojima, Takumi; Muranishi, Shozo; Sezaki, Hitoshi

CS Fac. Pharm. Sci., Kyoto Univ., Kyoto, Japan

SO Gann (1978), 69(6), 839-43

CODEN: GANNA2; ISSN: 0016-450X

DT Journal

LA English

IT 69898-92-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of)


RN 69898-92-6 HCAPLUS

CN Agarose, (1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)carbamimidate (9CI) (CA INDEX NAME)

CM 1

CRN 172963-26-7

CMF C10 H14 N4 O6



CM 2

CRN 9012-36-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L16 ANSWER 30 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI The synthesis, characterization, and preliminary biological evaluation of
1- β -D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin

GI



AB This paper describes the synthesis of a single diastereomer by conversion of ara-CMP [7075-11-8] to the nucleoside 5'-phosphomorpholidate [69467-87-4], followed by reaction with L- α -dipalmitoylphosphatidic acid pyridinium salt [69467-86-3] to give 1- β -D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin di-Na salt (I) [69483-93-8] in good yields. The separation of the product is described and its characterization by chromatog., elemental anal., and spectroscopic methods. The lipophilic nature of I renders it insol. in aqueous media and a method of sample preparation utilizing sonication techniques is

described which provides a clear solution suitable for biol. evaluation. In addition, the ability of I to inhibit the in vitro growth of L1210 cells and of mouse myeloma MPC 11 cells is described and compared with ara C [147-94-4] and its lipophilic prodrugs.

AN 1979:145575 HCAPLUS <<LOGINID::20081217>>

DN 90:145575

OREF 90:23005a,23008a

TI The synthesis, characterization, and preliminary biological evaluation of
1- β -D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin

AU MacCoss, Malcolm; Ryu, Eung K.; Matsushita, Tatsuo

CS Div. Biol. Med. Res., Argonne Natl. Lab., Argonne, IL, USA

SO Biochemical and Biophysical Research Communications (1978),
85(2), 714-23

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

IT 23113-01-1 31088-06-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antineoplastic activity of)

RN 23113-01-1 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 31088-06-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 31 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI N4-behenoyl-1- β -D-arabinofuranosylcytosine as a potential new
antitumor agent

GI



I

AB N4-acyl-1- β -D-arabinofuranosylcytosines, which are lipophilic antitumor analogs of 1- β -D-arabinofuranosylcytosine, were dissolved by the use of a detergent, HCO-60, and the differences in the antitumor activities when the drugs were administered to mice in the forms of solution or suspension were compared. N4-Stearoyl-1- β -D-arabinofuranosylcytosine (NSC 201290) [55726-44-8], which was the most active compound when administered as an aqueous suspension, diminished in its activity after it had been dissolved into a clear solution, whereas N4-behenoyl-1- β -D-arabinofuranosylcytosine (NSC 239336) (I) [55726-47-1] exhibited activities superior to those of the parent compound 1- β -D-arabinofuranosylcytosine when administered as a solution. Moreover, the high efficacy of I was long lasting in the host animal, regardless of the treatment schedules or the presence of the 1- β -D-arabinofuranosylcytosine-inactivating enzyme, cytidine deaminase.

AN 1977:527364 HCAPLUS <<LOGINID::20081217>>

DN 87:127364

OREF 87:20165a,20168a

TI N4-behenoyl-1- β -D-arabinofuranosylcytosine as a potential new antitumor agent

AU Aoshima, Michiko; Tsukagoshi, Shigeru; Sakurai, Yoshio; Ohishi, Junichi; Ishida, Torao; Kobayashi, Hidehiko

CS Cancer Chemother. Cent., Jap. Found. Cancer Res., Tokyo, Japan

SO Cancer Research (1977), 37(8, Pt. 1), 2481-6

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English


IT 55726-44-8 55726-47-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by)

RN 55726-44-8 HCAPLUS

CN Octadecanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 55726-47-1 HCAPLUS

CN Docosanamide, N-(1- β -D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 32 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Pharmacology of 5'-esters of 1-β-D-arabinofuranosylcytosine
 GI



AB Pharmacol. studies of 5'-esters of 1-β-D-arabinofuranosylcytosine (ara-C) were performed in 3 species (mouse, pig, and man). In mice, after a single i.p. injection of a suspension of tritiated 1-β-D-arabinofuranosylcytosine 5'-palmitate (I) [31088-06-9] at a therapeutic dose of 150 mg/kg, 30% of the administered radioactivity was recovered in the urine in 24 h and 56% was recovered after 7 days. Excretion was less rapid after s.c. administration. Ara-C and 1-β-D-arabinofuranosyluracil [3083-77-0] each accounted for about 50% of the excreted radioactivity, and no I was found. I concns. of greater than 0.1 μg/mL were detected 24 h after i.p. administration of I (150 mg/kg). Single doses of I were therapeutic against L1210 leukemic mice when administered 5-7 days before tumor inoculation. In a pig, after i.m. injection of tritiated I (60 mg/kg, two sites), only 7% of the administered radioactivity was recovered in the urine over a 1-week period. Similar low rates of excretion were also observed in patients treated i.m. with I or 1-β-D-arabinofuranosylcytosine 5'-benzoate [34270-10-5]. No ara-C was detected in the plasma, which is consistent with the absence of clin. toxicity or myelosuppression in Phase 1 trials of I at doses up to 1500 mg/m² every 3 weeks for as many as 8 courses.

AN 1977:511524 HCAPLUS <<LOGINID::20081217>>

DN 87:111524

OREF 87:17625a,17628a

TI Pharmacology of 5'-esters of 1-β-D-arabinofuranosylcytosine


AU Ho, D. H. W.; Neil, Gary L.

CS Univ. Texas Syst. Cancer Cent., M. D. Anderson Hosp. Tumor Inst., Houston, TX, USA

SO Cancer Research (1977), 37(6), 1640-3
 CODEN: CNREA8; ISSN: 0008-5472


DT Journal
 LA English
 IT 31088-06-9 34270-10-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. of)
 RN 31088-06-9 HCAPLUS
 CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 34270-10-5 HCAPLUS
 CN 2(1H)-Pyrimidinone, 4-amino-1-(5-O-benzoyl- β -D-arabinofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.





L16 ANSWER 33 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acids. 16. Orally active derivatives of ara-cytidine
 GI



AB Water-soluble derivs. of aracytidine (I) [147-94-4], including 5'-palmitoyl-

[59465-83-7], 5'-benzoyl- [59465-84-8], and 5'-(1-adamantoyl)aracytidine-HCl [59465-77-9] and their N4-(tert-butoxycarbonylglycyl-L-arginyl) derivs. were prepared and tested, along with the 5'-nicotinate-HCl [59465-85-9] and 5'-quinuclidinate-2HCl [59457-00-0] of I, for antitumor, immunosuppressive, and antiarthritic activities. Five of the compds. had oral activity superior to I in the L1210 leukemia mouse assay, while the adamantoyl derivative had oral activity approaching that of parenterally administered I. Four of these same compds. were also more effective immunosuppressants than I. None of the derivs. had significant antiinflammatory activity.


AN 1976:456666 HCAPLUS <<LOGINID::20081217>>
 DN 85:56666
 OREF 85:9091a,9094a
 TI Nucleic acids. 16. Orally active derivatives of ara-cytidine
 AU Wechter, W. J.; Gish, D. T.; Greig, M. E.; Gray, G. D.; Moxley, T. E.; Kuentzel, S. L.; Gray, L. G.; Gibbons, A. J.; Griffin, R. L.; Neil, G. L.
 CS Res. Div., Upjohn Co., Kalamazoo, MI, USA
 SO Journal of Medicinal Chemistry (1976), 19(8), 1013-17
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 IT 59457-00-0 59465-78-0 59465-85-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. of)
 RN 59457-00-0 HCAPLUS
 CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-azabicyclo[2.2.2]octylcarbonyl)- β -D-arabinofuranosyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 59465-78-0 HCAPLUS
 CN L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]glycyl-N-(1- β -D-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 59465-85-9 HCAPLUS
 CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(3-pyridinylcarbonyl)-β-D-arabinofuranosyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L16 ANSWER 34 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Platinum-(2,4-dioxypyrimidine) complex
 AB The title complexes were prepared by treating 2,4-dioxypyrimidine derivs. with cis-diaquadiammineplatinum(II) [20115-64-4] in a 2:1 to 1:1 mole ratio at 0-55°. The complexes showed antitumor, antiviral, and antibacterial activity, high water solubility, and low renal toxicity. For example, 0.01 mole cis-dichlorodiammineplatinum(II) [15663-27-1] was treated with 0.02 mole AgNO₃ in the dark to give cis-diaquadiammineplatinum(II). This complex was then treated with uracil in a 1:1 mole ratio at pH 6-7 to give a complex which showed antitumor, antibacterial, and antiviral activity.
 AN 1976:428777 HCAPLUS <<LOGINID::20081217>>
 DN 85:28777
 OREF 85:4645a,4648a
 TI Platinum-(2,4-dioxypyrimidine) complex
 IN Rosenberg, Barnett; Mansy, Samir A. L. A.; Van Camp, Loretta L.; Peresie,

Henry J.; Fischer, Robert George; Davidson, James P.
 PA Research Corp., USA
 SO Ger. Offen., 51 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2445418	A1	19760401	DE 1974-2445418	19740923 <--
	JP 58028278	B	19830615	JP 1974-112688	19740930 <--
PRAI	DE 1974-2445418		19740923	<--	
IT	1748-04-5D, Uridine, 2',3',5'-tribenzoate, platinum complexes RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antitumor activity of)				
RN	1748-04-5 HCAPLUS				
CN	Uridine, 2',3',5'-tribenzoate (CA INDEX NAME)				

Absolute stereochemistry.



IT 4105-38-8DP, Uridine, 2',3',5'-triacetate, platinum complexes
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antitumor activity of)
 RN 4105-38-8 HCAPLUS
 CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 35 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Reactions of 2-acyloxyisobutyryl halides with nucleosides. 8. Synthesis and biological evaluation of some 3'-acyl and 3',5'-diacyl derivatives of

1-β-D-arabinofuranosylcytosine

GI



AB A series of 37 3'-O-acyl (I; R = H, R1 = acyl) and 3',5'-di-O-acyl (I; R = R1 ; acyl) derivs. of 1-β-D-arabinofuranosylcytosine (I, R = R1 = H) (araC) [147-94-4] with saturated or unsatd. ester groups containing 2-22 C atoms

were prepared by hydrolytic cleavage of the corresponding 2,2'-anhydro derivs. (II). Three 5'-O-acyl derivs. (I; R = acyl, R1 = H) were prepared by reaction of araC-HCl [69-74-9] with the appropriate acyl chloride. All I showed cytotoxicity against HeLa cells comparable to araC with the exception of very long chain saturated and unsatd. esters. The 3'-monoesters were more active against Vaccinia and Herpes viruses than the diesters, with the C8-C12 3'-monoesters having activity comparable to araC. Against L1210 leukemia in mice the long chain mono- and diester derivs. had high activity with many long-term survivors.

AN 1976:144569 HCAPLUS <<LOGINID::20081217>>

DN 84:144569

OREF 84:23421a,23424a

TI Reactions of 2-acyloxyisobutyryl halides with nucleosides. 8. Synthesis and biological evaluation of some 3'-acyl and 3',5'-diacyl derivatives of 1-β-D-arabinofuranosylcytosine

AU Hamamura, Ernest K.; Prystasz, Miroslav; Verheyden, Julien P. H.; Moffatt, John G.; Yamaguchi, Kenji; Uchida, Naomi; Sato, Kosaburo; Nomura, Akio; Shiratori, Osamu; et al.

CS Inst. Mol. Biol., Syntex Res., Palo Alto, CA, USA

SO Journal of Medicinal Chemistry (1976), 19(5), 667-74

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT 31088-06-9P 34417-62-4P 36508-83-5P
38707-42-5P 38707-59-4P 50721-16-9P
53758-37-5P 53758-38-6P 53758-39-7P
53758-40-0P 53758-41-1P 53758-42-2P
53758-43-3P 53758-44-4P 53758-45-5P
53758-47-7P 53758-48-8P 53758-49-9P
53758-50-2P 53758-51-3P 53758-52-4P
58611-37-3P 58611-38-4P 58611-39-5P
58611-40-8P 58611-41-9P 58611-42-0P
58611-43-1P 58611-44-2P 58611-45-3P
58611-46-4P 58611-47-5P 58611-48-6P

58611-49-7P 58611-50-0P 58611-51-1P
58611-52-2P 58611-53-3P 58641-55-7P
58690-98-5P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and cytotoxicity of)

RN 31088-06-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)

L16 ANSWER 36 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents

AB Many of the complexes of diaquo species of cis-dichlorodiammineplatinum (II) and pyrimidines and substituted pyrimidines showed superior activity against the ascites Sarcoma 180 tumor in mice when compared to cis-dichlorodiammineplatinum [15663-27-1]. Activity was also shown against the Rauscher leukemia, Ehrlich ascites, and ADJ/PC6A tumors. The platinum-uracil complex caused only minor focal damage to the proximal convoluted tubules of the kidney. The methods for synthesis and characterization of some of the complexes are described, though the structure of the complexes are largely uncertain at this time.

AN 1975:508573 HCAPLUS <<LOGINID::20081217>>

DN 83:108573

OREF 83:16985a,16988a

TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents

AU Davidson, James P.; Faber, Paula J.; Fischer, Robert G., Jr.; Mansy, Samir; Peresie, Henry J.; Rosenberg, Barnett; VanCamp, Loretta

CS Dep. Biophys., Michigan State Univ., East Lansing, MI, USA

SO Cancer Chemotherapy Reports, Part 1 (1975), 59(2), 287-300

CODEN: CCROBU; ISSN: 0576-6559

DT Journal

LA English

IT 1748-04-5D, Uridine, 2',3',5'-tribenzoate, complex with platinum

4105-38-8D, Uridine, 2',3',5'-triacetate, complex with platinum


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibitor)

RN 1748-04-5 HCAPLUS


CN Uridine, 2',3',5'-tribenzoate (CA INDEX NAME)

Absolute stereochemistry.




RN 4105-38-8 HCAPLUS
CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 37 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Comparative chemotherapy of AKR lymphoma and human hematological neoplasia
AB Melphalan (I) [148-82-3] (7.7 mg/kg 4 times daily for 12 days) caused a 118% increase in life span of AKR mice with spontaneous lymphoma, as compared to a 75% life span increase when early L1210 leukemia was used for the assay. Several other antitumor drugs, including 5-fluorouracil (II) [51-21-8], vinblastine [865-21-4], daunorubicin [20830-81-3], 6-mercaptopurine [50-44-2], and procarbazine [671-16-9] were in reasonably good agreement in both systems, when they were compared at their optimal dosages for each system. The effectiveness of 27 chemotherapeutic drugs was tested in AKR mice with spontaneous lymphoma and the results were compared with those in L1210 transplanted tumors and with clin. information. The data indicated there is possibly a better correspondence of spontaneous AKR with non-Hodgkin's lymphoma and myeloma than for other hematol. cancers. There was no advantage in using the spontaneous AKR system for primary screening as compared to the early leukemia L1210 system. The AKR system might be useful for studying remission induction and maintenance, and for evaluation of prophylactic treatment as well as reinduction.
AN 1974:103722 HCAPLUS <<LOGINID::20081217>>
DN 80:103722
OREF 80:16627a,16630a
TI Comparative chemotherapy of AKR lymphoma and human hematological neoplasia
AU Frei, Emil III; Schabel, Frank M., Jr.; Goldin, Abraham
CS Child. Cancer Res. Found., Boston, MA, USA
SO Cancer Research (1974), 34(1), 184-93
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English
IT 31088-06-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by, tumor systems in evaluation of)
RN 31088-06-9 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(1-oxohexadecyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 38 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices

AB When administered s.c. to L1210 leukemic mice in Silastic implants, ara-C (1-β-D-arabinofuranosylcytosine) (I) [147-94-4], 1-β-D-arabinofuranosylcytosine 5'-adamantoate [34624-43-6], 1-β-D-arabinofuranosylcytosine 5'-acetate [31088-09-2], CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] [13010-47-4], and MeCCNU [1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea] [33073-59-5] significantly increased survival time and in the case of I, CCNU, and MeCCNU, resulted in a considerable number of cures. Silastic cylinders containing 625 mg I/kg, implanted up to 3 days prior to tumor inoculation yield significant therapeutic effects, suggesting that I was being released at a slow rate such that cytotoxic levels persisted in the mice for several days. This depot effect was confirmed by studies of I levels in the plasma and I excretion after administration of 14C-I. Silastic cylinders containing 25 mg CCNU/kg, when implanted 4 hr prior to tumor inoculation, showed activity, but no therapeutic effect was observed when administration was 24 hr prior to inoculation. The necessary exposure time for an optimum therapeutic effect was considerably longer for an S-phase specific agent such as I than for nonphase-specific agents such as CCNU.

AN 1972:522196 HCAPLUS <<LOGINID::20081217>>

DN 77:122196

OREF 77:20120h,20121a

TI Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices

AU Neil, G. L.; Scheidt, L. G.; Kuentzel, S. L.; Moxley, T. E.

CS Cancer Res., Upjohn Co., Kalamazoo, MI, USA

SO Chemotherapy (Basel, Switzerland) (1972), 18(1), 27-40

CODEN: CHTHBK; ISSN: 0009-3157

DT Journal

LA English

IT 23113-01-1 31088-09-2


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(leukemia treatment by, silicone rubber implants in)

RN 23113-01-1 HCAPLUS


CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 31088-09-2 HCAPLUS
 CN 2(1H)-Pyrimidinone, 1-(5-O-acetyl- β -D-arabinofuranosyl)-4-amino- (CA
 INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 39 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Immunosuppressive, antiviral, and antitumor activities of cytarabine derivatives
 AB A variety of cytarabine 5'-acylate derivs. (especially palmitoyl cytarabine [31088-06-9] and benzoyl cytarabine [34270-10-5]) were as effective as 5'-adamantoyl cytarabine [23113-01-1] in suppressing immune responses in rodents, as antitumor agents in mice, in protecting mice from the lethal effects of intracranial herpes simplex infection, and in inhibiting DNA synthesis in phytohemagglutinin-stimulated human lymphocytes. After injection of the insol. derivs. a finite time is required for dispersion and solubilization. After enzymic hydrolysis to the free acid and cytarabine (I) [147-94-4], the latter is then free to exert its inhibitory actions. The net effect is the maintenance of relatively low I levels for long periods.
 AN 1972:149009 HCAPLUS <<LOGINID::20081217>>
 DN 76:149009
 OREF 76:24215a,24218a
 TI Immunosuppressive, antiviral, and antitumor activities of cytarabine derivatives
 AU Gray, Gary D.; Nichol, F. Richard; Mickelson, M M.; Camiener, G. W.; Gish, Duane T.; Kelly, Robert C.; Wechter, W. J.; Moxley, Thomas E.; Neil, Gary L.
 CS Upjohn Res. Lab., Upjohn Co., Kalamazoo, MI, USA
 SO Biochemical Pharmacology (1972), 21(4), 465-75
 CODEN: BCPA6; ISSN: 0006-2952
 DT Journal
 LA English
 IT 23113-01-1 31088-04-7 31088-06-9
 31088-08-1 31088-09-2 31088-10-5
 31088-13-8 31088-14-9 31088-15-0
 31088-16-1 31088-20-7 31088-21-8
 31088-22-9 34270-10-5 35819-38-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 23113-01-1 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)

L16 ANSWER 40 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Biochemical and pharmacologic studies with
1- β -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot
form of cytarabine

AB 1- β -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614) (I)
[34624-43-6] decreased DNA synthesis but not RNA or protein synthesis in
cultured mouse L1210 leukemia cells. The decrease in growth of L1210
cells and human KB epidermoid carcinoma cells caused by I was prevented by
deoxycytidine [951-77-9]. I was hydrolyzed by mammalian blood plasma and
eserine sulfate [64-47-1] prevented this hydrolysis. Eserine sulfate
decreased the cytotoxicity of I toward L1210 cells. These results
indicate that hydrolysis of I to 1- β -D-arabinofuranosylcytosine
(cytarabine) [147-94-4] is required for cytotoxic activity.

AN 1972:135598 HCAPLUS <<LOGINID::20081217>>

DN 76:135598

OREF 76:21931a,21934a

TI Biochemical and pharmacologic studies with
1- β -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot
form of cytarabine

AU Neil, G. L.; Buskirk, H. H.; Moxley, T. E.; Manak, R. C.; Kuentzel, S. L.;
Bhuyan, B. K.

CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA

SO Biochemical Pharmacology (1971), 20(12), 3295-308
CODEN: BCPCA6; ISSN: 0006-2952

DT Journal

LA English


IT 23113-01-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by, cytarabine in relation to)

RN 23113-01-1 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 41 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acyl derivatives of 1- β -D-arabinofuranosylcytosine

AB 1-(2,3,5-Tri-O-butryl- β -D-arabinofuranosyl)cytosine (I) [34409-15-9]
and the corresponding 3,5-di-O-butryl derivative (II) of the anticancer drug

1- β -D-arabinofuranosylcytosine (III) [147-94-4] were active in vivo against leukemia L1210. I (450 mg/kg i.p.) produced >174% increase in life span in animals receiving 105 L1210 cells i.p. I was more active and less toxic than II, and was superior to III and tri-O-acetyl-III on a chronic schedule. The tetrabutryl derivative (IV) was inactive. I was prepared by acylation of III with butyric anhydride to IV, followed by N-deacylation with picric acid.

AN 1972:107849 HCAPLUS <<LOGINID::20081217>>

DN 76:107849

OREF 76:17337a,17340a

TI Acyl derivatives of 1- β -D-arabinofuranosylcytosine

AU Montgomery, John A.; Thomas, H. Jeanette

CS Kettering-Meyer Lab., South. Res. Inst., Birmingham, AL, USA

SO Journal of Medicinal Chemistry (1972), 15(1), 116-18

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT 34409-15-9 34409-16-0 34417-62-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibitor)

RN 34409-15-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,3,5-tris-O-(1-oxobutyl)- β -D-arabinofuranosyl]- (CA INDEX NAME)

L16 ANSWER 42 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor effect of 1- β -D-arabinofuranosylcytosine 5'-adamantoate (NSC117614) in L1210 leukemic mice

AB The effects of a new derivative of 1- β -D-arabinofuranosylcytosine (I), NSC 63878, 1- β -D-arabinofuranosylcytosine 5'-adamantoate, NSC 117,614 (II), on the survival of L1210 leukemic mice was studied. In all the treatment schedules investigated (single doses, short courses of daily doses, and widely spaced doses), II was therapeutically more effective than I. For a given total dose, the effectiveness of II was relatively insensitive to the schedule used. Single dose therapy with II was almost as effective as therapy with I on an "optimum" schedule (courses of multiple closely spaced doses with appropriate intervals for host recovery). II was effective when administered i.p. or s.c., and is active even when administered as much as 48 hr prior to tumor inoculation. This and other data (e.g., lack of reversal in vivo by deoxycytidine) suggest a sustained action effect.

AN 1970:443632 HCAPLUS <<LOGINID::20081217>>

DN 73:43632

OREF 73:7201a,7204a

TI Antitumor effect of 1- β -D-arabinofuranosylcytosine 5'-adamantoate (NSC117614) in L1210 leukemic mice

AU Neil, G. L.; Wiley, P. F.; Manak, R. C.; Moxley, T. E.

CS Upjohn Co., Kalamazoo, MI, USA

SO Cancer Research (1970), 30(4), 1047-54

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

IT 23113-01-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(neoplasm inhibition by)

RN 23113-01-1 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)-

β -D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 43 OF 43 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Aminoacyl nucleosides derived from the tumor inhibitor,
1-aminocyclopentanecarboxylic acid
AB The 2'(3')-O-adenosine and -uridine esters of
1-aminocyclopentanecarboxylic acid have been prepared They had no
significant effect against an exptl. plasma cell tumor in mice,
nor did they inhibit protein synthesis in vitro. Each aminoacyl derivative
was separated into its 2 components, which were characterized by N.M.R.
spectroscopy. No interconversion between the 2'- and 3'-substituted
nucleosides occurred, although base-catalyzed hydrolysis proceeded at a
rate comparable with that of other aminoacyl nucleosides. The possible
implications of these findings in protein biosynthesis are discussed.
Some related compds. derived from 6-(methylthio)purine are described.
AN 1969:522249 HCAPLUS <<LOGINID::20081217>>
DN 71:122249
OREF 71:22713a,22716a
TI Aminoacyl nucleosides derived from the tumor inhibitor,
1-aminocyclopentanecarboxylic acid
AU Jarman, Michael; Kuszmann, J.; Stock, J. A.
CS Roy. Cancer Hosp., London, UK
SO Biochemical Pharmacology (1969), 18(10), 2473-84
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English
IT 25521-40-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacology of)
RN 25521-40-8 HCAPLUS
CN Uridine, 2'-(1-aminocyclopentanecarboxylate) (8CI, 9CI) (CA INDEX NAME)

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:23:04 ON 19 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9
 DICTIONARY FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> exp 5-fluoroorotate/cn
E1      1      5-FLUORONORNICOTINE/CN
E2      1      5-FLUOROCTAETHYLPORPHYRIN/CN
E3      1 --> 5-FLUOROOROTATE/CN
E4      1      5-FLUOROOROTIC ACID/CN
E5      1      5-FLUOROOROTIC ACID AND STREPTOMYCIN MIXTURE/CN
E6      1      5-FLUOROOROTIC ACID METHYL ESTER/CN
E7      1      5-FLUOROOROTIC ALDEHYDE/CN
E8      1      5-FLUOROOXINDOLE/CN
E9      1      5-FLUOROOXINE/CN
E10     1      5-FLUOROPENT-2-YNE/CN
E11     1      5-FLUOROPENTANE-1,4-DIAMINE/CN
E12     1      5-FLUOROPENTANE-1,4-DIAMINE DIHYDROCHLORIDE/CN
```

```
=> s e3
L1      1 5-FLUOROOROTATE/CN
```

```
=> fiel hcaplus
FIEL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.61	5.82

FILE 'HCAPLUS' ENTERED AT 14:23:40 ON 19 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1
L2      281 L1

=> s uridine or cytidine
        29224 URIDINE
        14029 CYTIDINE
L3      38059 URIDINE OR CYTIDINE

=> s l2 and l3
L4      44 L2 AND L3

=> s l4 and (PY<1993 or AY<1993 or PRY<1993)
        14920430 PY<1993
        2629073 AY<1993
        2069789 PRY<1993
L5      36 L4 AND (PY<1993 OR AY<1993 OR PRY<1993)
```

```
=> file hcaplus
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                               ENTRY          SESSION
FULL ESTIMATED COST          5.38          11.20
```

FILE 'HCAPLUS' ENTERED AT 14:24:42 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)


HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=>

Uploading C:\Program Files\STNEXP\Queries\08460186acylated2.str



chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 30 31 32 33 34 35 38 39 41
42 43 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 24 25 26 27 28 29
chain bonds :
1-15 1-21 2-14 2-22 3-16 3-23 5-20 5-47 7-12 8-42 9-13 10-18 11-19
14-39

15-41 16-17 17-38 25-30 27-31 28-32 29-33 31-43 34-35
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11 24-29 24-25 25-26
26-27
27-28 28-29
exact/norm bonds :
1-2 1-5 1-15 2-3 2-14 3-4 4-5 5-47 6-11 6-7 7-8 7-12 8-9 8-42 9-10
9-13 10-11 14-39 15-41 17-38 24-29 24-25 25-26 25-30 26-27 27-28 27-31
28-29 31-43 34-35

exact bonds :
1-21 2-22 3-16 3-23 5-20 10-18 11-19 16-17 28-32 29-33

G1:H, [*1]

G2:[*2], [*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 38:CLASS 39:CLASS 41:CLASS 42:CLASS
43:CLASS 47:CLASS

Stereo Bonds:

14-2 (Single Hash).
15-1 (Single Hash).

Stereo Chiral Centers:

1 (Parity=Odd)
2 (Parity=Even)

Stereo RSS Sets:

Type=Relative (Default). 2 Nodes= 1 2
L6 STRUCTURE UPLOADED

=> s l6 sss full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 14:25:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 43389 TO ITERATE

100.0% PROCESSED 43389 ITERATIONS 1387 ANSWERS
SEARCH TIME: 00.00.01

L7 1387 SEA SSS FUL L6

L8 10564 L7

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.69

194.94

FILE 'REGISTRY' ENTERED AT 14:25:40 ON 19 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9

DICTIONARY FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\08460186not.str



```

chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 30 31 32 33 34 35 37 38 39
43
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 24 25 26 27 28 29
chain bonds :
1-15 1-21 2-14 2-22 3-16 3-23 5-20 5-43 7-12 8-38 9-13 10-18 11-19
14-35
15-37 16-17 17-34 25-30 27-31 28-32 29-33 31-39
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11 24-29 24-25 25-26
26-27
27-28 28-29
exact/norm bonds :
1-2 1-5 1-15 2-3 2-14 3-4 4-5 5-43 6-11 6-7 7-8 7-12 8-9 9-10 9-13
10-11 24-29 24-25 25-26 25-30 26-27 27-28 27-31 28-29
exact bonds :
1-21 2-22 3-16 3-23 5-20 8-38 10-18 11-19 14-35 15-37 16-17 17-34 28-32
29-33 31-39

```

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS 39:CLASS 43:CLASS

L9 STRUCTURE UPLOADED

=> s 19 sub-17

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s 19 sub=17

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 14:26:18 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 1387 TO ITERATE

100.0% PROCESSED 1387 ITERATIONS

303 ANSWERS

SEARCH TIME: 00.00.01

L10 303 SEA SUB=L7 SSS FUL L9

=> s 17 not l10

L11 1084 L7 NOT L10

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

42.56

237.50

FILE 'HCAPLUS' ENTERED AT 14:26:28 ON 19 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26

FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:22:42 ON 19 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:23:04 ON 19 DEC 2008

EXP 5-FLUOROOROTATE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 14:23:40 ON 19 DEC 2008

L2 281 S L1

L3 38059 S URIDINE OR CYTIDINE

L4 44 S L2 AND L3

L5 36 S L4 AND (PY<1993 OR AY<1993 OR PRY<1993)

FILE 'HCAPLUS' ENTERED AT 14:24:42 ON 19 DEC 2008

L6 STRUCTURE UPLOADED

S L6

FILE 'REGISTRY' ENTERED AT 14:25:28 ON 19 DEC 2008

L7 1387 S L6 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:25:29 ON 19 DEC 2008

L8 10564 S L7 SSS FULL

FILE 'REGISTRY' ENTERED AT 14:25:40 ON 19 DEC 2008

L9 STRUCTURE UPLOADED

L10 303 S L9 SUB=L7 FULL

L11 1084 S L7 NOT L10

FILE 'HCAPLUS' ENTERED AT 14:26:28 ON 19 DEC 2008

=> s l11

L12 1462 L11

=> s l2 and l12


L13 6 L2 AND L12

=> d l13 1-6 ti abs bib


L13 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of optically active radio-labeled acyclic nucleotide analogs as reverse transcriptase inhibitors

GI



I



II

AB Disclosed herein are isotopically labeled reverse transcriptase inhibitors, including acyclic nucleotide analogs I, wherein R1 and R2 independently are selected from H, lower alkyl, aralkyl, acyl; Z1 and Z2 independently form, a phospho-ester or phospho-amide, were prepared and used as optically active radio-labeled reverse transcriptase inhibitors. Also disclosed are methods for synthesizing such compds. in racemic and optically pure forms. In addition, methods for using the labeled compds., for example in positron emission tomog. (PET) monitoring of retrovirus activity, are disclosed. Thus, I (R1 = R2 = H, Z1 = Z2 = OH) was prepared via coupling of adenine derivative II with (diethoxyphosphoryl)methyl trifluoromethanesulfonate. Title compds. were tested in mice to measure the radioactivity comprises measuring the viral load in the subject's lymphatic tissue, gastrointestinal tract, tonsils, rectal mucosa, lymph nodes, central nervous system, thymus, testes or combinations thereof. The present compds. and methods may be used to determine dosages that avoid nephrotoxicity.

AN 2008:1338764 HCAPLUS <<LOGINID::20081219>>

DN 149:493909

TI Synthesis of optically active radio-labeled acyclic nucleotide analogs as reverse transcriptase inhibitors

IN Kieseletter, Dale O.; Di Mascio, Michele; Lim, Esther

PA United States Dept. of Health and Human Services, USA

SO PCT Int. Appl., 47pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008134578	A2	20081106	WO 2008-US61664	20080425
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US	2007-914732P	P	20070428		

L13 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Aza-quinolinol phosphonate integrase inhibitor compounds
 GI



AB Aza-quinolinol phosphonate compds. and methods for inhibition of HIV-integrase are disclosed. Formula I (where Ar = aryl, heteroaryl group; X1, X2, X3, X4, X5 = N, substituted nitrogen, substituted carbon, etc.; R6, R7, R8 = H, halogen, -OH, amino, ammonium, etc.; L = bond, O, S, alkylene, etc.). The compds. include at least one phosphonate group covalently attached at any site. 2,6-Diamino-(S)-9-[2-(phosphonomethoxy)propyl]purine.

AN 2005:283491 HCAPLUS <<LOGINID::20081219>>

DN 142:329814

TI Aza-quinolinol phosphonate integrase inhibitor compounds

IN Jin, Haolun; Kim, Choung U.; Nelson, Peter H.

PA Gilead Sciences, Inc., USA

SO PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028478	A1	20050331	WO 2004-US30743	20040917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004274493	A1	20050331	AU 2004-274493	20040917
	CA 2537325	A1	20050331	CA 2004-2537325	20040917
	US 20050137199	A1	20050623	US 2004-944118	20040917
	US 7462721	B2	20081209		
	EP 1664046	A1	20060607	EP 2004-784571	20040917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070185007	A1	20070809	US 2007-569655	20070123
PRAI	US 2003-504050P	P	20030919		
	WO 2004-US30743	W	20040917		

OS MARPAT 142:329814

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

AB The subject invention discloses compds., compns. and methods for treatment
and prevention of toxicity due to chemotherapeutic agents and antiviral
agents. Disclosed are acylated derivs. of non-methylated pyrimidine
nucleosides. These compds. are capable of attenuating damage to the
hematopoietic system in animals receiving antiviral or antineoplastic
chemotherapy. Oral administration of triacetyluridine ameliorated the
hematol. toxicity of 5-fluorouracil. Effects of other derivs. are also
presented. Synthesis of ethoxycarbonyluridine is included.

AN 1995:756200 HCAPLUS <<LOGINID::20081219>>

DN 123:160865

OREF 123:28387a

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

IN Von Borstel, Reid Warren; Bamat, Michael Kevin

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514		
	IN 1992-CA473	A1	19920706		
	WO 1993-US12689	W	19931230		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
OS	MARPAT 123:160865				

L13 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with
acylated pyrimidine nucleosides

AB The toxicity of antiviral and antineoplastic agents, resulting from their
damage to the hematopoietic system or mucosal tissue, is prevented or
treated with acylated derivs. of nonmethylated pyrimidine nucleosides.
These derivs. may themselves be antineoplastic, antiviral, or antimalarial
agents; they may be administered together with inhibitors of uridine
phosphorylase, of cytidine deaminase, or of nucleotide transport. Thus,
oral administration of triacetyluridine (500 mg/kg 8 times in 2 days)
rescued mice from the hematol. toxicity of 5-fluorouracil (150 mg/kg
i.p.), as shown by leukocyte and platelet counts.

AN 1993:205218 HCAPLUS <<LOGINID::20081219>>

DN 118:205218

OREF 118:35053a,35056a

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with
acylated pyrimidine nucleosides

IN Von Borstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9301202	A1	19930121	WO 1992-US5324	19920625
	W: AU, BR, CA, FI, JP, KR, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2111571	A1	19930121	CA 1992-2111571	19920625
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625
	CA 2504078	C	20070828		
	AU 9222544	A	19930211	AU 1992-22544	19920625
	AU 667676	B2	19960404		
	EP 594667	A1	19940504	EP 1992-914215	19920625
	EP 594667	B1	20010919		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06508846	T	19941006	JP 1993-502244	19920625
	JP 2584947	B2	19970226		
	AT 205850	T	20011015	AT 1992-914215	19920625
	ES 2160579	T3	20011116	ES 1992-914215	19920625
	ZA 9204975	A	19930428	ZA 1992-4975	19920703
	IL 102407	A	19970110	IL 1992-102407	19920703
	CN 1071577	A	19930505	CN 1992-108868	19920704
	CN 1050996	C	20000405		
	IN 175688	A1	19950812	IN 1992-CA473	19920706
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	HK 1003424	A1	20020215	HK 1998-102605	19980327
	AU 9952624	A	19991202	AU 1999-52624	19991001
	GR 3036749	T3	20011231	GR 2001-401606	20010927
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1991-724340	A	19910705		
	US 1992-903107		19920625		
	CA 1992-2111571	A3	19920625		
	WO 1992-US5324	A	19920625		
	IN 1992-CA473	A1	19920706		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
OS	MARPAT 118:205218				

L13 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Polymeric compositions capable of releasing a bioactive substance at a controlled rate

AB A polymeric composition that releases a bioactive substance at a controlled rate comprises a polymer having a bioactive organic moiety bonded on ≥ 1 side chain through a metal ester bonding. A polymer was prepared by heating a mixture of Et acrylate 60, 2-ethylhexyl acrylate 25, acrylic acid 15, AIBN 2, xylene 120 and BuOH 30 parts at 110-120°, for 2 h. This polymer (100 parts) was heated with 14.4 parts 5-quinolinecarboxylic acid and 7.7 parts Ni(OH)₂ at 120° for 2 h to give a controlled-release material.

AN 1988:26959 HCAPLUS <<LOGINID::20081219>>

DN 108:26959

OREF 108:4463a,4466a

TI Polymeric compositions capable of releasing a bioactive substance at a controlled rate

IN Yamamori, Naokia; Ohsugi, Hiroharu; Eguchi, Yoshuo; Yokoi, Junji

PA Nippon Paint Co., Ltd., Japan

SO Eur. Pat. Appl., 37 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 220965	A2	19870506	EP 1986-308477	19861030
	EP 220965	A3	19900214		
	EP 220965	B1	19920122		
	R: DE, FR, GB, NL				
	JP 62101653	A	19870512	JP 1985-243593	19851030
	JP 07108927	B	19951122		
	AU 8664512	A	19870507	AU 1986-64512	19861028
	AU 598761	B2	19900705		
	DK 8605169	A	19870501	DK 1986-5169	19861029
	NO 8604320	A	19870504	NO 1986-4320	19861029
	NO 171533	B	19921221		
	NO 171533	C	19930331		
	CA 1325970	C	19940111	CA 1986-521750	19861029
	US 5298569	A	19940329	US 1993-1417	19930107
PRAI	JP 1985-243593	A	19851030		
	US 1986-924823	B1	19861030		
	US 1988-267698	B1	19881103		
	US 1990-622112	B1	19901205		

L13 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation, antibacterial effects and enzymic degradation of
 5-fluorouracil nucleosides

AB 5-Fluorouracil nucleosides of 15 aldopentofuranoses, and
 1-(S)-(2,3-dihydroxypropyl)-5-fluorouracil were prepared by fluorination of
 the perbenzoylated nucleosides with F in AcOH followed by debenzoylation,
 and used in the study of the in vitro cleavage by the cell-free extract from
 Escherichia coli and of antibacterial effect on E. coli.
 1-Allyl-5-fluorouracil was prepared from CH₂:CHCH₂Br and
 2,4-bis(trimethylsilyloxy)-5-fluoropyrimidine and also tested. The cell
 exts. cleaved 5-fluorouracil only from the nucleosides with
 R-configuration of the nucleoside C atom and trans-position of 3'-OH of
 furanose to the base, i.e. from β-D-ribofuranoside,
 2-deoxy-β-D-ribofuranoside, 5-deoxy-β-D-ribofuranoside,
 β-D-arabinofuranoside, α-L-lyxofuranoside, and
 2-deoxy-α-L-lyxofuranoside, which also exhibited antibacterial
 activity (ID₅₀ 4 + 10⁻⁵- 2.5 + 10⁻⁷M). The antibacterial
 activity of uncleavable 1-(2-deoxy-β-L-ribofuranosyl)-,
 1-(2-deoxy-α-D-ribofuranosyl)-, and
 1-(2-deoxy-α-D-lyxofuranosyl)-5-fluorouracil (ID₅₀ 1.0-2.5 +
 10⁻⁵M), which can be reversed by 2'-deoxyuridine but not by thymidine, was
 explained by enzymic transdeoxyribosylation leading to cleavable
 5-fluoro-2'-deoxyuridine.

AN 1981:157178 HCAPLUS <<LOGINID::20081219>>

DN 94:157178

OREF 94:25713a,25716a

TI Preparation, antibacterial effects and enzymic degradation of
 5-fluorouracil nucleosides

AU Schwarz, Beatrice; Cech, Dieter; Holy, Antonin; Skoda, Jan

CS Sekt. Chem., Humboldt Univ. Berlin, Berlin, Ger. Dem. Rep.

SO Collection of Czechoslovak Chemical Communications (1980), 45(11), 3217-30
 CODEN: CCCCAK; ISSN: 0366-547X

DT Journal

LA English

=> s malaria or antimalarial
21456 MALARIA
12712 ANTIMALARIAL
L14 27122 MALARIA OR ANTIMALARIAL

=> s l12 and l14
L15 3 L12 AND L14

=> d l15 1-3 ti abs bib

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis and characterization of cytidine derivatives that inhibit the
kinase IspE of the non-mevalonate pathway for isoprenoid biosynthesis
AB The enzymes of the non-mevalonate pathway for isoprenoid biosynthesis are
attractive targets for the development of novel drugs against
malaria and tuberculosis. This pathway is used exclusively by the
corresponding pathogens, but not by humans. A series of water-soluble,
cytidine-based inhibitors that were originally designed for the fourth
enzyme in the pathway, IspD, were shown to inhibit the subsequent enzyme,
the kinase IspE (from *Escherichia coli*). The binding mode of the
inhibitors was verified by co-crystal structure anal., using Aquifex
aeolicus IspE. The crystal structures represent the first reported
example of a co-crystal structure of IspE with a synthetic ligand and
confirmed that ligand binding affinity originates mainly from the
interactions of the nucleobase moiety in the cytidine binding pocket of
the enzyme. In contrast, the appended benzimidazole moieties of the
ligands adopt various orientations in the active site and establish only
poor intermol. contacts with the protein. Defined binding sites for
sulfate ions and glycerol mols., components in the crystallization buffer, near
the well-conserved ATP-binding Gly-rich loop of IspE were observed. The
crystal structures of *A. aeolicus* IspE nicely complement the one from *E.*
coli IspE for use in structure-based design, namely by providing
invaluable structural information for the design of inhibitors targeting
IspE from *Mycobacterium tuberculosis* and *Plasmodium falciparum*. Similar
to the enzymes from these pathogens, *A. aeolicus* IspE directs the OH group
of a tyrosine residue into a pocket in the active site. In the *E. coli*
enzyme, on the other hand, this pocket is lined by phenylalanine and has a
more pronounced hydrophobic character.
AN 2008:526915 HCAPLUS <<LOGINID::20081219>>
DN 149:79826
TI Synthesis and characterization of cytidine derivatives that inhibit the
kinase IspE of the non-mevalonate pathway for isoprenoid biosynthesis
AU Crane, Christine M.; Hirsch, Anna K. H.; Alphey, Magnus S.; Sgraja, Tanja;
Lauw, Susan; Illarionova, Victoria; Rohdich, Felix; Eisenreich, Wolfgang;
Hunter, William N.; Bacher, Adelbert; Diederich, Francois
CS Laboratorium fuer Organische Chemie, HCI, ETH Zuerich, Zurich, CH-8093,
Germany
SO ChemMedChem (2008), 3(1), 91-101
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Crystal structure of erythrocyte binding domain of EBA-175 antigen for
screening and designing antimalarial or malaria
vaccine
AB The present invention provides three-dimensional structural information

for region II of the erythrocyte binding antigen 175 (EBA-175) derived from Plasmodium falciparum. Specifically, the present invention provides three-dimensional structural information of erythrocytic receptor binding sites of EBA-175 RII. The three-dimensional structural information is useful in drug design aimed at blocking receptor interaction with EBA-175. Computerized methods for drug design and methods for identifying compds. binding to EBA-175 RII are also provided.

AN 2007:203201 HCAPLUS <<LOGINID::20081219>>

DN 146:272534

TI Crystal structure of erythrocyte binding domain of EBA-175 antigen for screening and designing antimalarial or malaria vaccine

IN Joshua-Tor, Leemor; Tolia, Niraj H.; Lee Sim, B. Kim

PA USA

SO U.S. Pat. Appl. Publ., 68pp., Cont.-in-part of U.S. Ser. No. 861,615.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20070043208	A1	20070222	US 2005-183666	20050718
PRAI	US 2003-476489P	P	20030606		
	US 2004-861615	A2	20040604		

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

AB The toxicity of antiviral and antineoplastic agents, resulting from their damage to the hematopoietic system or mucosal tissue, is prevented or treated with acylated derivs. of nonmethylated pyrimidine nucleosides. These derivs. may themselves be antineoplastic, antiviral, or antimalarial agents; they may be administered together with inhibitors of uridine phosphorylase, of cytidine deaminase, or of nucleotide transport. Thus, oral administration of triacetyluridine (500 mg/kg 8 times in 2 days) rescued mice from the hematol. toxicity of 5-fluorouracil (150 mg/kg i.p.), as shown by leukocyte and platelet counts.

AN 1993:205218 HCAPLUS <<LOGINID::20081219>>

DN 118:205218

OREF 118:35053a,35056a

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

IN Von Borstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9301202	A1	19930121	WO 1992-US5324	19920625
	W: AU, BR, CA, FI, JP, KR, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2111571	A1	19930121	CA 1992-2111571	19920625
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625
	CA 2504078	C	20070828		
	AU 9222544	A	19930211	AU 1992-22544	19920625
	AU 667676	B2	19960404		

EP 594667	A1	19940504	EP 1992-914215	19920625
EP 594667	B1	20010919		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06508846	T	19941006	JP 1993-502244	19920625
JP 2584947	B2	19970226		
AT 205850	T	20011015	AT 1992-914215	19920625
ES 2160579	T3	20011116	ES 1992-914215	19920625
ZA 9204975	A	19930428	ZA 1992-4975	19920703
IL 102407	A	19970110	IL 1992-102407	19920703
CN 1071577	A	19930505	CN 1992-108868	19920704
CN 1050996	C	20000405		
IN 175688	A1	19950812	IN 1992-CA473	19920706
IN 177670	A1	19970215	IN 1994-CA701	19940902
HK 1003424	A1	20020215	HK 1998-102605	19980327
AU 9952624	A	19991202	AU 1999-52624	19991001
GR 3036749	T3	20011231	GR 2001-401606	20010927
AU 2002320811	A1	20030403	AU 2002-320811	20021223
AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI US 1991-724340	A	19910705		
US 1992-903107		19920625		
CA 1992-2111571	A3	19920625		
WO 1992-US5324	A	19920625		
IN 1992-CA473	A1	19920706		
AU 1995-29150	A3	19950630		
AU 1999-52624	A3	19991001		
AU 2002-320811	A3	20021223		
OS MARPAT 118:205218				

=> d his

(FILE 'HOME' ENTERED AT 14:22:42 ON 19 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:23:04 ON 19 DEC 2008
EXP 5-FLUOROOROTATE/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 14:23:40 ON 19 DEC 2008

L2 281 S L1

L3 38059 S URIDINE OR CYTIDINE

L4 44 S L2 AND L3

L5 36 S L4 AND (PY<1993 OR AY<1993 OR PRY<1993)

FILE 'HCAPLUS' ENTERED AT 14:24:42 ON 19 DEC 2008

L6 STRUCTURE UPLOADED
S L6

FILE 'REGISTRY' ENTERED AT 14:25:28 ON 19 DEC 2008

L7 1387 S L6 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:25:29 ON 19 DEC 2008

L8 10564 S L7 SSS FULL

FILE 'REGISTRY' ENTERED AT 14:25:40 ON 19 DEC 2008

L9 STRUCTURE UPLOADED

L10 303 S L9 SUB=L7 FULL

L11 1084 S L7 NOT L10

FILE 'HCAPLUS' ENTERED AT 14:26:28 ON 19 DEC 2008

L12 1462 S L11

L13 6 S L2 AND L12

L14 27122 S MALARIA OR ANTIMALARIAL
L15 3 S L12 AND L14

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.57	269.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:27:31 ON 19 DEC 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 15:40:52 ON 19 DEC 2008
FILE 'HCAPLUS' ENTERED AT 15:40:52 ON 19 DEC 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.57	269.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.26	271.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

FILE 'HCAPLUS' ENTERED AT 15:41:15 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s uridine/cn

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L17 7325 L16

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	282.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'REGISTRY' ENTERED AT 15:41:31 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9
DICTIONARY FILE UPDATES: 18 DEC 2008 HIGHEST RN 1086785-80-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s uridine/cn

L18 1 URIDINE/CN

=> s cytidine/cn

L19 1 CYTIDINE/CN

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.76	293.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'HCAPLUS' ENTERED AT 15:41:48 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l18/thu or l19/thu

7325 L18

1079165 THU/RL

304 L18/THU

(L18 (L) THU/RL)

4524 L19

1079165 THU/RL

169 L19/THU

(L19 (L) THU/RL)

L20 390 L18/THU OR L19/THU

=> s cancer or antitumor

385943 CANCER

269466 ANTITUMOR

L21 536186 CANCER OR ANTITUMOR

=> s l20 and l21

L22 143 L20 AND L21

=> s l22 and (PY<1993 or AY<1993 or PRY<1993)

14920430 PY<1993
2629073 AY<1993
2069789 PRY<1993

L23 15 L22 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d 123 1-15 ti abs bib

L23 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

AB Compsds., compns., and methods are disclosed for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

AN 1999:670113 HCAPLUS <<LOGINID::20081219>>

DN 131:281604

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

IN Von Borstel, Reid; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5968914	A	19991019	US 1995-472210	19950607 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--
	US 5736531	A	19980407	US 1993-176485	19931230 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5770582	A	19980623	US 1995-419767	19950410 <--
	US 5691320	A	19971125	US 1995-465454	19950605 <--
	US 6054441	A	20000425	US 1995-463790	19950605 <--
	US 6060459	A	20000509	US 1995-465016	19950605 <--
	US 7307166	B1	20071211	US 1995-463771	19950605 <--
	US 6258795	B1	20010710	US 1995-466145	19950606 <--
	US 6316426	B1	20011113	US 1995-466144	19950606 <--
	US 6232298	B1	20010515	US 1995-479519	19950607 <--
	US 6274563	B1	20010814	US 1995-479349	19950607 <--
	US 6348451	B1	20020219	US 1995-478736	19950607 <--
	US 6919320	B1	20050719	US 1995-473331	19950607 <--
	CA 2223640	A1	19961219	CA 1996-2223640	19960606
	WO 9640165	A1	19961219	WO 1996-US10067	19960606

	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG		
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN		
AU	9661114	A	19961230	AU 1996-61114 19960606
AU	724805	B2	20000928	
EP	831849	A1	19980401	EP 1996-918461 19960606
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI		
CN	1192149	A	19980902	CN 1996-195929 19960606
JP	10511689	T	19981110	JP 1997-502184 19960606
JP	2003201240	A	20030718	JP 2003-721 19960606
EP	1491201	A1	20041229	EP 2004-23557 19960606
EP	1491201	B1	20060322	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL		
AT	320813	T	20060415	AT 2004-23557 19960606
ES	2257721	T3	20060801	ES 2004-23557 19960606
PT	1491201	T	20060831	PT 2004-23557 19960606
HK	1072897	A1	20060512	HK 2005-105421 19981003
US	20010025032	A1	20010927	US 1999-249790 19990216 <--
US	6344447	B2	20020205	
AU	9952624	A	19991202	AU 1999-52624 19991001
US	6743782	B1	20040601	US 2000-494242 20000131 <--
AU	2002320811	A1	20030403	AU 2002-320811 20021223
US	20040033981	A1	20040219	US 2003-601863 20030624 <--
US	20040192635	A1	20040930	US 2004-824501 20040415 <--
US	20040220134	A1	20041104	US 2004-855835 20040528 <--
AU	2005232288	A1	20051201	AU 2005-232288 20051110
JP	2006137772	A	20060601	JP 2005-380457 20051228 <--
JP	2008019268	A	20080131	JP 2007-233452 20070907 <--
PRAI	US 1987-115923	B2	19871028	<--
	US 1987-115929	B2	19871028	<--
	US 1989-438493	B2	19890627	<--
	US 1990-487984	B2	19900205	<--
	US 1991-724340	B2	19910705	<--
	US 1992-903107	B2	19920625	<--
	US 1993-61381	B2	19930514	
	US 1993-176485	A2	19931230	
	US 1988-186031	B2	19880425	<--
	EP 1988-910239	A3	19881027	<--
	JP 1988-509176	A3	19881027	<--
	JP 1994-303877	A3	19881027	<--
	JP 2000-379524	A3	19881027	<--
	US 1989-341925	B1	19890421	<--
	US 1990-533933	B1	19900605	<--
	US 1990-438493	B2	19900626	<--
	US 1991-653882	B2	19910208	<--
	US 1991-737913	B3	19910729	<--
	CA 1992-2111571	A3	19920625	<--
	IN 1992-CA473	A1	19920706	<--
	US 1992-911379	A3	19920713	<--
	US 1992-925931	B2	19920807	<--
	US 1992-958598	B3	19921007	<--
	US 1992-987730	B2	19921208	<--
	US 1992-997657	A3	19921230	<--
	US 1993-96407	B1	19930726	
	US 1993-98884	B1	19930729	
	US 1993-153163	A1	19931117	

US	1993-158799	B2	19931201
US	1994-266897	B3	19940701
US	1994-289214	A3	19940812
US	1995-419767	A3	19950410
US	1995-463740	A1	19950605
US	1995-472210	A	19950607
AU	1995-29150	A3	19950630
EP	1996-918461	A3	19960606
JP	1997-502184	A3	19960606
WO	1996-US10067	W	19960606
HK	1998-111095	A3	19981003
AU	1999-52624	A3	19991001
US	2000-494242	A3	20000131
AU	2002-320811	A3	20021223
JP	2005-380457	A3	20051228

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Determination of prodrugs metabolizable by the liver and therapeutic use thereof

AB A method of ascertaining if a prodrug is useful for treating a disease is disclosed. The prodrug is acceptable if it is metabolized in liver cells by aldehyde oxidase to produce an active drug or metabolite. Prodrugs are shown equally effective in treating diseases as the active drug itself with many benefits and without as many associated side effects. Methods for treating cancers with e.g. 5-iodo-2-pyrimidinone-deoxyribose are also described.

AN 1998:186491 HCAPLUS <<LOGINID::20081219>>

DN 128:239464

OREF 128:47257a,47260a

TI Determination of prodrugs metabolizable by the liver and therapeutic use thereof

IN Cheng, Yung-Chi; Chang, Chien-Neng

PA Yale University, USA

SO U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 701,462, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5728684	A	19980317	US 1994-146164	19940419 <--
	ZA 9203495	A	19930331	ZA 1992-3495	19920514 <--
	WO 9220816	A1	19921126	WO 1992-US4142	19920515 <--
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE				
	IL 121375	A	19981206	IL 1992-121375	19920515 <--
PRAI	US 1991-701462	B2	19910515	<--	
	US 1992-829474	B2	19920203	<--	
	WO 1992-US4142	W	19920515	<--	
	IL 1992-101879	A3	19920515	<--	

OS MARPAT 128:239464

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.

AN 1997:141015 HCAPLUS <<LOGINID::20081219>>
 DN 126:139905
 OREF 126:26891a
 TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
 IN Vonborstel, Reid W.; Bamat, Michael K.
 PA Pro-Neuron, Inc., USA
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 10511689	T	19981110	JP 1997-502184	19960606
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1995-472210	A	19950607		
	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205	<--	
	US 1991-724340	B2	19910705	<--	
	US 1992-903107	B2	19920625	<--	
	IN 1992-CA473	A1	19920706	<--	
	US 1993-61381	B2	19930514		
	US 1993-176485	A2	19931230		
	AU 1995-29150	A3	19950630		
	WO 1996-US10067	W	19960606		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		

L23 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

AB Pyrimidine nucleotide precursors, including acyl derivs. of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use

in enhancing resistance to sepsis or systemic inflammation, are disclosed. Triacetyluridine improved survival of mice treated with a LD of Salmonella typhimurium endotoxin, reduced endotoxin-caused tissue damage, reduced mortality in viral hepatitis in mice, and improved recovery from ethanol intoxication.

AN 1996:205056 HCAPLUS <<LOGINID::20081219>>

DN 124:250921

OREF 124:46221a,46224a

TI Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

IN Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9601115	A1	19960118	WO 1995-US8259	19950630
	W: AU, CA, CN, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IN	177670	A1	19970215	IN 1994-CA701	19940902 <--
US	5691320	A	19971125	US 1995-465454	19950605 <--
US	6232298	B1	20010515	US 1995-479519	19950607 <--
CA	2193967	A1	19960118	CA 1995-2193967	19950630
CA	2193967	C	20070911		
AU	9529150	A	19960125	AU 1995-29150	19950630
AU	712679	B2	19991111		
EP	768883	A1	19970423	EP 1995-924764	19950630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN	1156409	A	19970806	CN 1995-194806	19950630
JP	10505578	T	19980602	JP 1996-503935	19950630
CN	101066276	A	20071107	CN 2006-10105555	19950630
AU	9952624	A	19991202	AU 1999-52624	19991001
AU	2002320811	A1	20030403	AU 2002-320811	20021223
US	20030212036	A1	20031113	US 2003-421831	20030424
US	20040033981	A1	20040219	US 2003-601863	20030624 <--
US	20040220134	A1	20041104	US 2004-855835	20040528 <--
AU	2005232281	A1	20051201	AU 2005-232281	20051110
AU	2005232286	A1	20051201	AU 2005-232286	20051110
AU	2005232288	A1	20051201	AU 2005-232288	20051110
JP	2008007525	A	20080117	JP 2007-250303	20070926
PRAI	US 1994-266897	A	19940701		
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-438493	B2	19900626	<--	
	IN 1992-CA473	A1	19920706	<--	
	US 1992-987730	B2	19921208	<--	
	US 1993-158799	B2	19931201		
	US 1995-463740	A1	19950605		
	US 1995-479519	A1	19950607		
	AU 1995-29150	A3	19950630		
	CN 1995-194806	A3	19950630		
	JP 1996-503935	A3	19950630		
	WO 1995-US8259	W	19950630		
	AU 1999-52624	A3	19991001		
	US 2000-702876	A3	20001101		
	AU 2002-320811	A3	20021223		

TI Magnetic liquid compositions for imaging contrast agents
 AB Magnetic liquid compns. are prepared from physiol. tolerated dispersions of stabilized superparamagnetic particles in water or aqueous salt solution and reactive stabilizer substances chemical bonded over phosphate or phosphonate or carboxylate groups to the surface of the superparamagnetic particles. The reactive stabilizer substances stabilize and chemical bond diagnostic and pharmacol. active substances. The bonded stabilizer substances protect against aggregation. Dextran phosphate was treated with magnetite to form a magnetic liquid which was further carboxymethylated and reacted with anti-human Ig. The resulting magnetic liquid composition can be used for NMR diagnosis or in vitro diagnosis (no data). Preparation of other compns. for NMR or ultrasound imaging is also described.

AN 1993:229355 HCAPLUS <<LOGINID::20081219>>

DN 118:229355

OREF 118:39559a,39562a

TI Magnetic liquid compositions for imaging contrast agents

IN Pilgrimm, Herbert

PA Silica Gel Gesellschaft mbH adsorptions-Technik, Apparatebau, Germany

SO U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 173,590, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5160725	A	19921103	US 1991-638134	19910104 <--
	DE 3709851	A1	19881006	DE 1987-3709851	19870324 <--
PRAI	DE 1987-3709851	A	19870324	<--	
	US 1988-173590	B2	19880325	<--	

L23 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Relationships between the chromatographic retention data and the effects of nucleoside derivatives in highly metastatic 3LL cells

AB The effect of 21 nucleoside derivs. on the [3H]-thymidine cellular uptake and on the incorporation into DNA of highly metastatic 3LL (Lewis lung carcinoma) cells has been measured. Hydrophobic and hydrophilic mol. parameters (the adsorption capacity, specific adsorption surface, lipophilicity and specific hydrophobic surface area) have been determined by using TLC. Stepwise linear regression anal. and principal component anal. have been applied in order to reveal the relationships between the mol. parameters and the effect of the nucleoside derivs. on highly metastatic 3LL cells. The first principal component obtained from the measured activity data could be attributed to the change of [3H]-thymidine cellular uptake caused by the nucleoside, while the second principal component could be regarded as the measure of the effect on the DNA incorporation of [3H]-thymidine. The effect of nucleosides on the [3H]-thymidine uptake could be explained by the specific hydrophobic and adsorption surface area of the nucleoside, on the other hand the effect on the DNA incorporation could be described by the adsorption characteristics (specific hydrophilic surface area and adsorption capacity) of the derivs.

AN 1992:645002 HCAPLUS <<LOGINID::20081219>>

DN 117:245002

OREF 117:42171a,42174a

TI Relationships between the chromatographic retention data and the effects of nucleoside derivatives in highly metastatic 3LL cells

AU Pogany, G.; Cserhati, T.; Olah, J.; Valko, K.

CS Jt. Res. Organ., Hung. Acad. Sci., Budapest, H-1086, Hung.

SO Journal of Pharmaceutical and Biomedical Analysis (1992), 10(7), 495-500

CODEN: JPBADA; ISSN: 0731-7085

DT Journal

LA English

L23 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI A study on the synthesis and biological activity of nucleoside chemotherapeutic agents

AB Various 5-substituted 5'-amino-5'deoxyuridine conjugates of amino acids, peptides, and penicillin G, 5'-monophosphate-fatty acid derivs. were prepared 5'-Amino-5'deoxyuridinecyclo(Phe-Asp) and 5'-iodo-5'deoxyuridine-penicillin G were the most efficient compds. against microorganisms such as Staphylococcus aureus and L5178 murine lymphoma cells. 5'-Monophosphates were more active than simple uridine derivs. suggesting that other modified nucleoside 5'-phosphates should be examined as prodrugs. The MICs of the compds. prepared are tabulated.

AN 1992:439820 HCAPLUS <<LOGINID::20081219>>

DN 117:39820

OREF 117:6839a,6842a

TI A study on the synthesis and biological activity of nucleoside chemotherapeutic agents

AU Kang, Shin Won; Kim, Kyong Hee; Shine, Jung Hee; Lee, Bong Hun; Jang, Tae Sik

CS Coll. Nat. Sci., Pusan Natl. Univ., Pusan, 609-735, S. Korea

SO Misaengmul Hakhoechi (1991), 29(6), 353-60
CODEN: MIHCAR; ISSN: 0440-2413

DT Journal

LA Korean

L23 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Antitumor activity in association with thermochromic change of platinum pyrimidine greens against murine and human tumor cells

AB The antitumor activity of Pt-uridine-greens against various murine and human tumor cells was examined Pt greens showed outstanding cytotoxic activity towards a variety of murine and human tumor cells such as L1210, S-180, Daudi, HeLa and U937. A remarkable active fraction could be identified from HPLC anal. with a gel column. The activity is associated with thermochromic change of the green materials. In addition, examns. of size distribution of cells have suggested that Pt greens act as a replication inhibitor.

AN 1991:240070 HCAPLUS <<LOGINID::20081219>>

DN 114:240070

OREF 114:40305a,40308a

TI Antitumor activity in association with thermochromic change of platinum pyrimidine greens against murine and human tumor cells

AU Okada, Tomoko; Shimura, Takehiko; Okuno, Hiroaki

CS Natl. Chem. Lab. Ind., Tsukuba, 305, Japan

SO Inorganica Chimica Acta (1990), 178(1), 13-15
CODEN: ICHAA3; ISSN: 0020-1693

DT Journal

LA English

L23 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Convenient synthesis of anticancer cis-diammineplatinum pyrimidine green analogs by one-pot reaction and their evaluation of antitumor activities in vitro

AB cis-Diammineplatinum greens containing uracil, uridine, 5-fluorouracil, uridine-5'-monophosphate, and thymidine etc. have been synthesized by a 1-pot reaction. The reaction is fast, efficient and highly reliable, proceeding via in-situ generation of an aqua complex. High antitumor activity against L1210 cells has been shown with Pt pyrimidine green prepared by the 1-pot reaction. The products have accumulation effects as oligomer complexes on the active site, probably nuclear DNA. The influence of the ligands on the biol. activity is also

discussed.

AN 1991:73983 HCAPLUS <<LOGINID::20081219>>

DN 114:73983

OREF 114:12413a,12416a

TI Convenient synthesis of anticancer cis-diammineplatinum pyrimidine green analogs by one-pot reaction and their evaluation of antitumor activities in vitro

AU Shimura, Takehiko; Tomohiro, Takenori; Okuno, Hiroaki

CS Natl. Chem. Lab. Ind., Tsukuba, Japan

SO Kagaku Gijutsu Kenkyusho Hokoku (1990), 85(1), 11-15

CODEN: KGKHEP; ISSN: 0388-3213

DT Journal

LA Japanese

L23 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Platinum complexes as atitumor agents

AB [(H2N)2Pt(H2O)2]2X [X = (NO3-)2 or (ClO4-)2] is treated with uridine, thymidine, uracil, thymine, 2'-deoxyuridine, uridine-5'-mopophosphate, or 5-fluorouracil in the presence of H2O2 to form a Pt complex showing antitumor activity. A solution of cis-diaquodiamine Pt(II) sulfate (preparation given) in H2SO4 was successively treated with uridine, 0.5 N NaOH (to pH 4.3), and 1% H2O2 to give a Pt complex. The complex (10 µg/mL) inhibited the growth of L1210 tumor cells by 92.8%.

AN 1990:70002 HCAPLUS <<LOGINID::20081219>>

DN 112:70002

OREF 112:11759a,11762a

TI Platinum complexes as atitumor agents

IN Okuno, Hiroaki; Shimura, Takehiko; Tomohiro, Takenori

PA Agency of Industrial Sciences and Technology, Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 01125325	A	19890517	JP 1987-284567	19871111 <--
PRAI	JP 1987-284567		19871111	<--	

L23 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI In vitro antitumor activity of platinum pyrimidine greens obtained by one-pot synthesis on L1210 cells

AB Platinum pyrimidine complexes were prepared by the 1-pot method (described previously). The complexes were tested for biol. activity as leukemic tumor inhibitors. The inhibitory activity of these compds. is comparable to that of cisplatin with MIC values ranging from 0.85 to 3.6 µm.

AN 1989:470416 HCAPLUS <<LOGINID::20081219>>

DN 111:70416

OREF 111:11695a,11698a

TI In vitro antitumor activity of platinum pyrimidine greens obtained by one-pot synthesis on L1210 cells

AU Okuno, Hiroaki; Shimura, Takehiko; Uemura, Toshimasa; Nakanishi, Hiroshi; Tomohiro, Takenori

CS Natl. Chem. Lab. Ind., Tsukuba, 305, Japan

SO Inorganica Chimica Acta (1989), 157(2), 161-3

CODEN: ICHAA3; ISSN: 0020-1693

DT Journal

LA English

L23 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Manufacture of antitumor platinum green complexes

AB Antitumor Pt green complexes are prepared by reacting [(NH₃)₂Pt(H₂O)₂]X [X = SO₄²⁻, (NO₃)₂] with uridine or thymidine in the presence of H₂O₂ or a photosensitizer. cis-Diaquodiammineplatinum(II) sulfate (0.3 mmol) in 3 mL water was reacted with 73.2 mg uridine at pH 4.3 in the presence of 1% H₂O₂ to obtain 70.6 mg Pt green complex m. >300°. The complex (70 mg/kg) was administered i.p. to mice with transplanted leukemia cell L1210. The average survival time was >60 days vs. 10 days for controls.

AN 1988:622457 HCAPLUS <<LOGINID::20081219>>

DN 109:222457

OREF 109:36633a,36636a

TI Manufacture of antitumor platinum green complexes

IN Okuno, Hiroaki; Sasaki, Takuma; Yonemitsu, Tsukasa

PA Yoshitomi Pharmaceutical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 63044591	A	19880225	JP 1986-189316	19860812 <--
PRAI	JP 1986-189316		19860812	<--	

L23 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of antitumor platinum pyrimidine blues. Optimized reaction conditions and purification by gel filtration

AB A method is given for the efficient and highly reproducible preparation of platinum blues in a reaction of diaquo derivative of cis-Pt(NH₃)₂I₂, and nucleosides (uridine, 2'-deoxyuridine, uridine-5'-monophosphate) via air oxidation reaction with heating. Gel filtration method was successfully used for purification of the products. Notably, uridine green species rather than the blue complexes gave remarkably high antitumor activity against L1210 cells.

AN 1988:485068 HCAPLUS <<LOGINID::20081219>>

DN 109:85068

OREF 109:14035a,14038a

TI Synthesis of antitumor platinum pyrimidine blues. Optimized reaction conditions and purification by gel filtration

AU Okuno, Yohmei; Tomohiro, Takenori; Shimura, Takehiko

CS Natl. Chem. Lab. Ind., Tsukuba, Japan

SO Kagaku Gijutsu Kenkyusho Hokoku (1988), 83(1), 27-33

CODEN: KGKHEP; ISSN: 0388-3213


DT Journal

LA Japanese

L23 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside

GI



I

AB Lipophilic N1-acetyl and N4-chloroacetyl derivs. (I, R = H, ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H or Cl) of cytidine, 2'-deoxycytidine and cytosine arabinoside (Ara-C) were prepared by acetylation and chloroacetylation, resp. Their toxicity to A(Ti)Cl-3 hamster fibrosarcoma cells was determined I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = Cl) were potent with no colonies surviving at concns. of 10⁻⁴, 10⁻⁴, and 10⁻⁶M, resp. I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H) showed comparatively poor toxicity with 95, 77 and 87% survival of colonies, resp. N4-Chloroacetyl-2'-deoxycytidine and N4-chloroacetyl-Ara-C underwent hydrolysis in phosphate-buffered saline at 50° to yield the parent nucleosides and the N3-carboxymethyl derivs. via 1-H-2,3-dihydro-2,5-dioxoimidazo[1,2-c]pyrimidines.

AN 1988:142952 HCAPLUS <<LOGINID::20081219>>
 DN 108:142952
 OREF 108:23279a,23282a
 TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside
 AU Ariatti, Mario; Jones, Peter A.
 CS Dep. Biochem., Univ. Durban-Westville, Durban, 4000, S. Afr.
 SO Biochemistry International (1987), 15(6), 1097-103
 CODEN: BIINDF; ISSN: 0158-5231
 DT Journal
 LA English

L23 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Structure-activity consideration of novel anticancer platinum pyrimidine "greens"
 AB Pt pyrimidine greens were very effective against L1210 cells, but the blues were inactive. A clear relationship between the activity and size of Pt-green mols. was observed; smaller mols. with up to Pt-decanuclear complexes were much more active than larger ones. Formation of macrocells by the greens was found for the 1st time with L1210 cells. The more active the green complex is, the denser is the population of the macrocells. These findings could be related to the membrane permeability.

AN 1988:142864 HCAPLUS <<LOGINID::20081219>>
 DN 108:142864
 OREF 108:23263a,23266a
 TI Structure-activity consideration of novel anticancer platinum pyrimidine "greens"
 AU Shimura, Takehiko; Tomohiro, Takenori; Maruno, Kiyoshi; Fujimoto, Yasuo; Okuno, Yohmei
 CS Natl. Chem. Lab. Ind., Tsukuba, 305, Japan
 SO Chemical & Pharmaceutical Bulletin (1987), 35(12), 5028-31
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English

=> s antiviral or HIV or (human immunodeficiency) or AZT

70786 ANTIVIRAL
 82116 HIV
 2100784 HUMAN
 83490 IMMUNODEFICIENCY
 70144 HUMAN IMMUNODEFICIENCY
 (HUMAN(W) IMMUNODEFICIENCY)
 4024 AZT

L24 145941 ANTIVIRAL OR HIV OR (HUMAN IMMUNODEFICIENCY) OR AZT

=> s 120 and 124

L25 58 L20 AND L24

=> s 125 and (PY<1993 or AY<1993 or PRY<1993)

14920430 PY<1993

2629073 AY<1993

2069789 PRY<1993

L26 5 L25 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d 126 1-5 ti abs bib

L26 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Treatment of chemotherapeutic agent and antiviral agent toxicity
with acylated pyrimidine nucleosides

AB Compds., compns., and methods are disclosed for treatment and prevention
of toxicity due to chemotherapeutic agents and antiviral agents.
Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides.
These compds. are capable of attenuating damage to the hematopoietic
system in animals receiving antiviral or antineoplastic
chemotherapy.

AN 1999:670113 HCAPLUS <<LOGINID::20081219>>

DN 131:281604

TI Treatment of chemotherapeutic agent and antiviral agent toxicity
with acylated pyrimidine nucleosides

IN Von Borstel, Reid; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5968914	A	19991019	US 1995-472210	19950607 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--
	US 5736531	A	19980407	US 1993-176485	19931230 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5770582	A	19980623	US 1995-419767	19950410 <--
	US 5691320	A	19971125	US 1995-465454	19950605 <--
	US 6054441	A	20000425	US 1995-463790	19950605 <--
	US 6060459	A	20000509	US 1995-465016	19950605 <--
	US 7307166	B1	20071211	US 1995-463771	19950605 <--
	US 6258795	B1	20010710	US 1995-466145	19950606 <--
	US 6316426	B1	20011113	US 1995-466144	19950606 <--
	US 6232298	B1	20010515	US 1995-479519	19950607 <--
	US 6274563	B1	20010814	US 1995-479349	19950607 <--

US 6348451	B1	20020219	US 1995-478736	19950607 <--
US 6919320	B1	20050719	US 1995-473331	19950607 <--
CA 2223640	A1	19961219	CA 1996-2223640	19960606
WO 9640165	A1	19961219	WO 1996-US10067	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9661114	A	19961230	AU 1996-61114	19960606
AU 724805	B2	20000928		
EP 831849	A1	19980401	EP 1996-918461	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1192149	A	19980902	CN 1996-195929	19960606
JP 10511689	T	19981110	JP 1997-502184	19960606
JP 2003201240	A	20030718	JP 2003-721	19960606
EP 1491201	A1	20041229	EP 2004-23557	19960606
EP 1491201	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL				
AT 320813	T	20060415	AT 2004-23557	19960606
ES 2257721	T3	20060801	ES 2004-23557	19960606
PT 1491201	T	20060831	PT 2004-23557	19960606
HK 1072897	A1	20060512	HK 2005-105421	19981003
US 20010025032	A1	20010927	US 1999-249790	19990216 <--
US 6344447	B2	20020205		
AU 9952624	A	19991202	AU 1999-52624	19991001
US 6743782	B1	20040601	US 2000-494242	20000131 <--
AU 2002320811	A1	20030403	AU 2002-320811	20021223
US 20040033981	A1	20040219	US 2003-601863	20030624 <--
US 20040192635	A1	20040930	US 2004-824501	20040415 <--
US 20040220134	A1	20041104	US 2004-855835	20040528 <--
AU 2005232288	A1	20051201	AU 2005-232288	20051110
JP 2006137772	A	20060601	JP 2005-380457	20051228 <--
JP 2008019268	A	20080131	JP 2007-233452	20070907 <--
PRAI US 1987-115923	B2	19871028	<--	
US 1987-115929	B2	19871028	<--	
US 1989-438493	B2	19890627	<--	
US 1990-487984	B2	19900205	<--	
US 1991-724340	B2	19910705	<--	
US 1992-903107	B2	19920625	<--	
US 1993-61381	B2	19930514		
US 1993-176485	A2	19931230		
US 1988-186031	B2	19880425	<--	
EP 1988-910239	A3	19881027	<--	
JP 1988-509176	A3	19881027	<--	
JP 1994-303877	A3	19881027	<--	
JP 2000-379524	A3	19881027	<--	
US 1989-341925	B1	19890421	<--	
US 1990-533933	B1	19900605	<--	
US 1990-438493	B2	19900626	<--	
US 1991-653882	B2	19910208	<--	
US 1991-737913	B3	19910729	<--	
CA 1992-2111571	A3	19920625	<--	
IN 1992-CA473	A1	19920706	<--	
US 1992-911379	A3	19920713	<--	
US 1992-925931	B2	19920807	<--	
US 1992-958598	B3	19921007	<--	
US 1992-987730	B2	19921208	<--	

US	1992-997657	A3	19921230	<--
US	1993-96407	B1	19930726	
US	1993-98884	B1	19930729	
US	1993-153163	A1	19931117	
US	1993-158799	B2	19931201	
US	1994-266897	B3	19940701	
US	1994-289214	A3	19940812	
US	1995-419767	A3	19950410	
US	1995-463740	A1	19950605	
US	1995-472210	A	19950607	
AU	1995-29150	A3	19950630	
EP	1996-918461	A3	19960606	
JP	1997-502184	A3	19960606	
WO	1996-US10067	W	19960606	
HK	1998-111095	A3	19981003	
AU	1999-52624	A3	19991001	
US	2000-494242	A3	20000131	
AU	2002-320811	A3	20021223	
JP	2005-380457	A3	20051228	

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Compositions of chemotherapeutic agent or antiviral agent with
acylated pyrimidine nucleosides

AB The subject invention discloses compds., compns. and methods for treatment
and prevention of toxicity due to chemotherapeutic agents and
antiviral agents. Disclosed are acylated derivs. of
non-methylated pyrimidine nucleosides. These compds. are capable of
attenuating damage to the hematopoietic system in animals receiving
antiviral or antineoplastic chemotherapy. Thus, biol activity of
5-fluorouracil is reported.

AN 1998:236253 HCAPLUS <<LOGINID::20081219>>

DN 128:266247

OREF 128:52559a,52562a

TI Compositions of chemotherapeutic agent or antiviral agent with
acylated pyrimidine nucleosides

IN Von Borstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5736531	A	19980407	US 1993-176485	19931230 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--

US	5470838	A	19951128	US	1992-997657	19921230	<--
US	5583117	A	19961210	US	1993-140475	19931025	<--
US	6020320	A	20000201	US	1993-153163	19931117	<--
IN	177670	A1	19970215	IN	1994-CA701	19940902	<--
US	5770582	A	19980623	US	1995-419767	19950410	<--
US	5691320	A	19971125	US	1995-465454	19950605	<--
US	6054441	A	20000425	US	1995-463790	19950605	<--
US	6060459	A	20000509	US	1995-465016	19950605	<--
US	7307166	B1	20071211	US	1995-463771	19950605	<--
US	6258795	B1	20010710	US	1995-466145	19950606	<--
US	6316426	B1	20011113	US	1995-466144	19950606	<--
US	5968914	A	19991019	US	1995-472210	19950607	<--
US	6232298	B1	20010515	US	1995-479519	19950607	<--
US	6274563	B1	20010814	US	1995-479349	19950607	<--
US	6348451	B1	20020219	US	1995-478736	19950607	<--
US	6919320	B1	20050719	US	1995-473331	19950607	<--
US	7166581	B1	20070123	US	1995-473330	19950607	<--
US	20010025032	A1	20010927	US	1999-249790	19990216	<--
US	6344447	B2	20020205				
AU	9952624	A	19991202	AU	1999-52624	19991001	
US	6743782	B1	20040601	US	2000-494242	20000131	<--
AU	2002320811	A1	20030403	AU	2002-320811	20021223	
US	20040033981	A1	20040219	US	2003-601863	20030624	<--
US	20040192635	A1	20040930	US	2004-824501	20040415	<--
US	20040220134	A1	20041104	US	2004-855835	20040528	<--
AU	2005232288	A1	20051201	AU	2005-232288	20051110	
JP	2006137772	A	20060601	JP	2005-380457	20051228	<--
JP	2008019268	A	20080131	JP	2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--			
	US 1987-115929	B2	19871028	<--			
	US 1989-438493	B2	19890627	<--			
	US 1990-487984	B2	19900205	<--			
	US 1991-724340	B2	19910705	<--			
	US 1992-903107	B2	19920625	<--			
	US 1993-61381	B2	19930514				
	US 1988-186031	B2	19880425	<--			
	EP 1988-910239	A3	19881027	<--			
	JP 1988-509176	A3	19881027	<--			
	JP 1994-303877	A3	19881027	<--			
	JP 2000-379524	A3	19881027	<--			
	US 1989-341925	B1	19890421	<--			
	US 1990-533933	B1	19900605	<--			
	US 1990-438493	B2	19900626	<--			
	US 1991-653882	B2	19910208	<--			
	US 1991-737913	B3	19910729	<--			
	CA 1992-2111571	A3	19920625	<--			
	IN 1992-CA473	A1	19920706	<--			
	US 1992-911379	A3	19920713	<--			
	US 1992-925931	B2	19920807	<--			
	US 1992-958598	B3	19921007	<--			
	US 1992-987730	B2	19921208	<--			
	US 1992-997657	A3	19921230	<--			
	US 1993-96407	B1	19930726				
	US 1993-98884	B1	19930729				
	US 1993-153163	A1	19931117				
	US 1993-158799	B2	19931201				
	US 1993-176485	A2	19931230				
	US 1994-266897	B3	19940701				
	US 1994-289214	A3	19940812				
	US 1995-419767	A3	19950410				
	US 1995-463740	A1	19950605				

US 1995-472210	A1	19950607
AU 1995-29150	A3	19950630
AU 1999-52624	A3	19991001
US 2000-494242	A3	20000131
AU 2002-320811	A3	20021223
JP 2005-380457	A3	20051228

OS MARPAT 128:266247

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.

AN 1997:141015 HCAPLUS <<LOGINID::20081219>>

DN 126:139905

OREF 126:26891a

TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides

IN Vonborstel, Reid W.; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640165	A1	19961219	WO 1996-US10067	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	AU 9661114	A	19961230	AU 1996-61114	19960606
	AU 724805	B2	20000928		
	EP 831849	A1	19980401	EP 1996-918461	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 10511689	T	19981110	JP 1997-502184	19960606
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1995-472210	A	19950607		
	US 1987-115923	B2	19871028	<--	
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-487984	B2	19900205	<--	
	US 1991-724340	B2	19910705	<--	

US 1992-903107	B2	19920625	<--
IN 1992-CA473	A1	19920706	<--
US 1993-61381	B2	19930514	
US 1993-176485	A2	19931230	
AU 1995-29150	A3	19950630	
WO 1996-US10067	W	19960606	
AU 1999-52624	A3	19991001	
AU 2002-320811	A3	20021223	

L26 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

AB The subject invention discloses compds., compns. and methods for treatment
and prevention of toxicity due to chemotherapeutic agents and
antiviral agents. Disclosed are acylated derivs. of
non-methylated pyrimidine nucleosides. These compds. are capable of
attenuating damage to the hematopoietic system in animals receiving
antiviral or antineoplastic chemotherapy. Oral administration of
triacytyluridine ameliorated the hematol. toxicity of 5-fluorouracil.
Effects of other derivs. are also presented. Synthesis of
ethoxycarbonyluridine is included.

AN 1995:756200 HCAPLUS <<LOGINID::20081219>>

DN 123:160865

OREF 123:28387a

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

IN Von Borstel, Reid Warren; Bamat, Michael Kevin

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514		
	IN 1992-CA473	A1	19920706	<--	
	WO 1993-US12689	W	19931230		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
OS	MARPAT 123:160865				

L26 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Improved synthesis and in vitro antiviral activities of
5-cyanouridine and 5-cyano-2'-deoxyuridine

GI



AB 5-Cyanouridine (I) [4425-57-4] and 5-cyano-2'-deoxyuridine (II) [26639-00-9] were prepared by treatment of the appropriate acetylated 5-bromouracil nucleoside with NaCN or KCN in Me₂SO followed by deblocking. I had no significant in vitro activity against vaccinia virus, herpes simplex-1, or vesicular stomatitis virus, while II, lacking activity against herpes simplex, gave significant inhibition of vaccinia virus. Replacement of the 5-halogen substituent decreases, but does not abolish, antiviral activity.

AN 1977:415731 HCAPLUS <<LOGINID::20081219>>

DN 87:15731

OREF 87:2409a,2412a

TI Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine

AU Torrence, Paul F.; Bhooshan, Bharant; Descamps, Johan; De Clercq, Erik

CS Natl. Inst. Arthritis, Metab. Dig. Dis., NIH, Bethesda, MD, USA

SO Journal of Medicinal Chemistry (1977), 20(7), 974-6

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

=> s malaria or antimalarial or fluoroorotate

21456 MALARIA

12712 ANTIMALARIAL

98 FLUOROOROTATE

L27 27200 MALARIA OR ANTIMALARIAL OR FLUOROOROTATE

=> s 120 and 127


L28 3 L20 AND L27

=> d 128 1-3 ti abs bib

L28 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases

GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

AN 2005:99470 HCAPLUS <<LOGINID::20081219>>

DN 142:197889

TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases

IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott

PA Bayer Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009961	A2	20050203	WO 2004-US23500	20040722
	WO 2005009961	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259760	A1	20050203	AU 2004-259760	20040722
	CA 2532865	A1	20050203	CA 2004-2532865	20040722
	US 20050038080	A1	20050217	US 2004-895985	20040722
	EP 1663978	A2	20060607	EP 2004-786091	20040722
	EP 1663978	B1	20071128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004012219	A	20060822	BR 2004-12219	20040722
	CN 1856469	A	20061101	CN 2004-80021091	20040722
	JP 2006528196	T	20061214	JP 2006-521221	20040722
	ES 2297490	T3	20080501	ES 2004-786091	20040722
	KR 2006052866	A	20060519	KR 2006-701558	20060123
	MX 2006PA00860	A	20060720	MX 2006-PA860	20060123
	IN 2006DN00402	A	20070824	IN 2006-DN402	20060123
	NO 2006000870	A	20060407	NO 2006-870	20060222
PRAI	US 2003-489102P	P	20030723		

US 2004-540326P P 20040202
WO 2004-US23500 W 20040722
OS CASREACT 142:197889

L28 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of aryl ureas containing pyridine, quinoline and isoquinoline
N-oxide functionality as kinase inhibitors
GI



AB The title ureas containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom MLBNHCONHA [A = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl; B = (un)substituted phenylene, naphthylene, 5-6 membered monocyclic heteroarylene, 8-10 membered bicyclic heteroarylene; L = (CH₂)_mO(CH₂)_l, (CH₂)_m(CH₂)_l, (CH₂)_mCO(CH₂)_l, etc.; m, l = 0-4; M = (un)substituted pyridine-1-oxide, quinoline-1-oxide, isoquinoline-1-oxide; with the provisos] which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders, were claimed. Preparation of two ureas such as I [R = H, Me] which are not compds. of the invention, and have been distinguished from the compds. of the invention by a proviso, was described. Pharmaceutical composition comprising the title ureas was claimed.

AN 2003:656581 HCAPLUS <<LOGINID::20081219>>
DN 139:197370

TI Preparation of aryl ureas containing pyridine, quinoline and isoquinoline
N-oxide functionality as kinase inhibitors

IN Dumas, Jacques; Scott, William J.; Riedl, Bernd

PA Bayer Corporation, USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003068229	A1	20030821	WO 2003-US4110	20030211
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003209119	A1	20030904	AU 2003-209119	20030211

	US 20030216396	A1	20031120	US 2003-361850	20030211
	US 20070265315	A1	20071115	US 2007-775457	20070710
PRAI	US 2002-354935P	P	20020211		
	US 2003-361850	B1	20030211		
	WO 2003-US4110	W	20030211		

OS MARPAT 139:197370

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

AB The subject invention discloses compds., compns. and methods for treatment
and prevention of toxicity due to chemotherapeutic agents and antiviral
agents. Disclosed are acylated derivs. of non-methylated pyrimidine
nucleosides. These compds. are capable of attenuating damage to the
hematopoietic system in animals receiving antiviral or antineoplastic
chemotherapy. Oral administration of triacetyluridine ameliorated the
hematol. toxicity of 5-fluorouracil. Effects of other derivs. are also
presented. Synthesis of ethoxycarbonyluridine is included.

AN 1995:756200 HCAPLUS <<LOGINID::20081219>>

DN 123:160865

OREF 123:28387a

TI Acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents

IN Von Borstel, Reid Warren; Bamat, Michael Kevin

PA Pro-Neuron, Inc., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514		
	IN 1992-CA473	A1	19920706		
	WO 1993-US12689	W	19931230		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		
OS	MARPAT 123:160865				